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palavras-chave 
 
Cimentos de fosfatos de cálcio, biovidro, substitutos ósseos, cimentos prontos-
a-usar, putty, injectabilidade, tempo de presa, regeneração óssea, monetite, 
bioactivo, osteoconductividade 
 
resumo 
 
 
Nos últimos anos, o desenvolvimento e a inovação de novos substitutos 
ósseos tem revolucionado a vida de milhões de doentes. O objetivo deste 
trabalho é o desenvolvimento e caracterização de um sistema bioativo, 
injectável e pronto-a-usar (putty) para regeneração óssea. A fase sólida é 
constituída por pós de fosfato tricálcico beta (β-TCP), biovidro FastOs 
(FastOs®BG) e fosfato monocálcico monohidratado (MCPM), enquanto a fase 
líquida é o glicerol (G). A síntese dos pós de β-TCP foi obtida por reações de 
precipitação seguida de tratamento térmico; os pós de FastOs®BG foram 
obtidos por fusão e arrefecimento em água fria (fritagem) (melt-quenching). A 
caracterização dos pós foi feita por difracção de raios-X (XRD) e medição dos 
tamanhos de partícula. 
O sistema injectável pronto-a-usar foi preparado através da mistura das fases 
sólida e líquida e colocado em seringas seladas com tampa roscada. Do ponto 
de vista de aplicação clínica, o sistema foi caracterizado tendo em conta a sua 
injectabilidade, tempo de presa (setting time, ST) e resistência mecânica. A 
análise estrutural do sistema também foi realizada, através de XRD, 
espectroscopia de infravermelho com transformada de Fourier (FTIR) e 
microscopia eletrónica de varrimento (SEM). 
O sistema injectável pronto-a-usar tem uma razão em peso sólido/líquido (S/L) 
de 3,3, um ST médio de ~25 min, ~96% de injectabilidade, e 6 MPa de 
resistência máxima à compressão. Deste modo, o sistema injetável 
demonstrou excelentes resultados de injectabilidade, tendo-se verificado ainda 
a ausência do efeito de filter pressing e propriedades mecânicas aceitáveis. A 
análise estrutural dos cimentos endurecidos revelou a formação de cristais de 
monetite recobertos por uma camada apatítica amorfa após imersão em PBS e 
em água.  
Os resultados obtidos são promissores e permitem concluir que o sistema 
injetável pronto-a-usar possui excelentes propriedades de manipulação do 
ponto de vista clínico.  
De acordo com a Directiva 93/42/CEE o sistema injetável é considerado um 
dispositivo médico de classe III. Com o objectivo de contribuir para o seu 
processo de lançamento comercial e seguindo os requisitos essenciais 
estabelecidos no anexo I da Directiva 93/42/CEE foi elaborado um relatório 
tendo em conta a avaliação clínica do sistema injectável. 
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Calcium phosphate cements, bioglass, bone substitutes, premixed cement, 
putty, injectability, self-setting, bone regeneration, monetite, bioactive, 
osteoconductivity 
 
abstract 
 
 
In recent years, the development and innovation of new bone substitutes has 
revolutionized the lives of millions of patients. The aim of this work is the 
development and characterization of a bioactive, injectable and ready-to-use 
system (also called putty or premixed cement) for bone regeneration. The solid 
phase is constituted by beta-tricalcium phosphate (β-TCP), FastOs® bioglass 
(FastOs® BG) and monocalcium phosphate monohydrate (MCPM) powders, 
while the liquid phase comprises glycerol (G). The synthesis of β-TCP powder 
was obtained by precipitation reactions followed by heat-treatment; FastOs® 
BG was obtained by melt-quenching. The characterization of the obtained 
powders was made through X-ray diffraction (XRD) and measurement of the 
mean particle sizes and particle size distribution. 
The putty was prepared by mixing the solid and liquid phases and placed in 
syringes with a screw cap. Regarding clinical application, injectability, setting 
time (ST) and mechanical strength were investigated to characterize the putty. 
Structural analyses of the putty were also performed by XRD, Fourier Tranform 
Infrared Spectroscopy (FTIR) and Scanning Electron Microscopy (SEM). 
The putty has a solid/liquid weight ratio (S/L) of 3.3, mean ST of ~25 min, ~96% 
of injectability and a maximum compressive strength of 6 MPa. Therefore, the 
putty exhibited excellent injectability results, absence of filter pressing effect 
and acceptable mechanical properties. The structural analysis of the hardened 
cements revealed the formation of monetite crystals covered by an amorphous 
apatitic layer after immersion in PBS and water.  
The results are encouraging and support the conclusion that ready-to-use 
injectable bone substitutes have excellent handling properties to be used 
clinically.  
In accordance with the Directive 93/42/EEC the putty is considered a class III 
medical device. In order to pave the way towards its commercial release and in 
order to meet the essential requirements set out in Annex I of the Directive 
93/42/EEC, a clinical evaluation has been carried out. 
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1. Introduction 
 
Over the last century, the emergence of new materials and surgical techniques has 
dramatically changed the lives of millions of patients. As defined by Chester in 1991, 
biomaterials are “materials intended for contact with biological systems to evaluate, 
treat, augment or replace any tissue, organ or function of the body”. Biomaterials play a 
key role in modern healthcare, essentially in remediating musculo-skeletal diseases, such 
as osteoporosis or fractures associated with the aging of the population.1 
The development of biomaterials used in orthopaedic surgery, traumatology and 
maxillofacial, particularly of bone substitutes has been remarkable. Following blood, bone 
is the second most transplanted tissue.1 
According to Mainard2, “all materials of human, vegetable or synthetic origin intended for 
human implantation with prospect of a reconstitution of bone capital, either for the 
strengthening of a bone structure or the filling of loss bone substance of traumatic or 
orthopaedic origin, can be considered bone substitutes”. 
The bone taken from the patient himself (autograft) is preferred for the treatment of 
bone defects, as it provides good results such as the reduced risk of rejection. The 
autografts are considered gold standard, but they also have disadvantages, as they 
expose the patient to a second surgery to retract bone tissue and can lead to weakening 
of the bone structure. The allografts, which consist in the implantation of bone tissue 
taken from one individual from the same species as the patient, may be an alternative but 
they have disadvantages, as causing the change of mechanical properties and the 
possibility to trigger a mechanism of immune rejection (that requires use of 
immunosuppressants). There are also xenografts, which originate from a non-human 
donor and have an increased risk of rejection and disease transmission. To solve all 
limitations associated to these grafts, synthetic bone substitutes (grafts) are now 
commonly used and represent a viable option for bone regeneration.1,3 
Ceramic biomaterials based on calcium phosphates such as hydroxyapatites (HA), 
tricalcium phosphates (TCP) and calcium phosphate cements (CPC) have been extensively 
4 
  
used as bone substitutes for clinical applications due to excellent biocompatibility and 
osteoconductive properties.4 
Bioactive glasses (BG) are also very popular and used among bone substitutes, due to 
their good biocompatibility in both bone and soft tissues. BG binds strongly to bone, 
promotes bone growth through the formation of an apatite layer and releases Ca, P and 
Si ions which stimulate osteogenesis.5 
The current major disadvantage of all orthopaedic implants is their existence in hardened 
form, which requires the surgeon to adjust the site of surgery to the implant or has yet to 
change the morphology to obtain a specific form applicable to the injury site. These 
complications can lead to an increase of bone loss, trauma in the surrounding tissue and 
prolongation of surgery. By contrast, CPC can be adjusted to the bone cavity without 
machining and have self-setting ability.6 
CPC can be mouldable or injectable and may be the solution for complex bone defects. 
However, CPC mixtures are prepared in the surgery room from components in powder 
and liquid that are supplied in fixed doses for each application. Even if it is not fully used, 
the surplus part sets and is discarded. Injectable systems based on bioactive materials 
such as bioactive glasses (BG) and calcium phosphates (CP) and a non-reactive liquid, 
supplied in syringes with screw cap, help overcome these difficulties. This type of ready-
to-use medical device allows an administration of the required dose and keep the surplus 
part to other subsequent applications until all the contents have been used. These are 
profiled as a very recent application as an injectable bone substitute (also called premixed 
calcium phosphate cement or putty) and it is expected that they can overcome the 
current limitations of CPC and implants and promote fast bone regeneration. 
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 1.1. Aim of thesis 
 
The main aim of this work is the development and characterization of a ready-to-use 
injectable bioactive system for bone regeneration. It is intended to obtain a solid, 
bioactive phase, consisting of FastOsBG and β-TCP powders and a liquid phase, non-
reactive, consisting of glycerol (G). Afterwards, a certain amount of monocalcium 
phosphate monohydrate (MCPM) will be added to confer self-setting capacity of the 
putty when it is in contact with physiological fluid. The setting time will be evaluated by 
immersing a mould with putty in PBS, so the components of the non-reactive liquid will 
diffuse and be replaced by water molecules. The compositions, 
morphology/microstructure, injectability, phase separation/filter pressing effect, 
mechanical properties and the bioactivity and biodegradability in vitro will also be 
investigated. The classification and clinical evaluation of the developed bone substitute 
will be made in accordance with the Directive 93/42/EEC. 
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2. State of the Art 
 
2.1 Bone anatomy and physiology 
 
The skeletal system is multifunctional. Its functionality is assured by bone growth, 
formation and remodelling, throughout life, by bone cells and also by mineralization 
which is regulated by extracellular bone matrix. The bone strength depends on several 
factors: the weight, the geometry and composition, the material properties and the 
microstructure.7 
The bone is a complex conjunctive tissue, highly organized and specialized, that performs 
different functions. It is physically characterized as a hard, rigid and strong tissue. 
Microscopic analysis reveals the presence of very few cells and intercellular substance 
formed by collagen fibres and hardened substance. The bone consists of bone cells 
(osteoblasts, osteocytes and osteoclasts) and extracellular matrix, differing from the 
other conjunctive tissues because its matrix is mineralized. In its composition is included 
33% organic matrix and 67% of inorganic compounds. The most abundant ion in the 
tissue are calcium and phosphorus, which form the most important mineral constituent 
hydroxyapatite (HA), which has the following stoichiometric chemical formula: Ca10 (PO4)6 
(OH)2.8 
 
2.1.1 Bone Macrostructure 
 
An adult human individual has a total of 213 bones, excluding the sesamoid. Each bone 
suffers constant changes throughout life. It grows to adapt to biomechanical forces, and 
remodels to remove old bone microscopically damaged, replacing it with new bone 
tissue, mechanically stronger to help preserve bone strength.7 
The bone is composed by two types of bone tissue: cortical/compact bone (80%) and 
cancellous/trabecular/spongy bone (20%). The cortical bone forms the bone cortex and 
10 
  
has a dense structure. It is the main component of the long bones of the arm, leg and 
other bones on which we require higher strength and stiffness. Trabecular bone normally 
occupies the inner region of the bone and is composed by thin plates, or trabeculae, on a 
loose mesh structure. Each trabecula contains collagen fibres arranged in parallel 
lamellae. It is highly vascular and frequently contains red bone marrow where the 
hematopoiesis (process by which blood cells are formed) takes place. It has a larger 
surface area, but is less dense, softer, weaker and less hard than the cortical bone.9 
The bones can also be classified as: long (e.g.: femur, tibia, humerus, radius), small (e.g.: 
carpal, tarsal), flat (e.g.: ribs, external, skull and shoulder blade), irregular (e.g.: vertebra) 
and sesamoid (patella and small bones of the foot). Each long bone can be divided into 
three regions, called epiphysis, metaphysis and diaphysis.10 
The bone surface is covered by periosteal and endosteal as connective tissue. The 
periosteum coats the outer surface of the bone, except the links that are protected by 
articular cartilage and consist on a fibrous outer layer composed by collagen fibers, 
fibroblasts, and an inner layer comprising mesenchymal stem cells - osteoprogenitor cells 
with the capacity to divide and differentiate into osteoblasts. The endosteal is connected 
to the inner surface of the bone, particularly on the surface of the medullary cavity of 
long bones. It is composed by osteoprogenitor cells and a small amount of connective 
tissue. Both surfaces, periosteal and endosteal, provide a continuous reinforcement of 
osteoprogenitor cells or new osteoblasts for repair or new bone growth.8 Figure 1 shows 
the structure of a long bone. 
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Figure 1 – Structure of a long bone (femur) (Adapted from Dorozhkin SV. 10). 
 
 
2.1.2 Bone Microstructure 
  
Bone tissue is constituted by four kinds of characteristic cells: osteoblasts, osteocytes, 
osteoclasts and bone mesenchymal stem cells. Osteoblasts are mononucleated cells that 
synthesize collagen or non-collagenous proteins and are responsible for mineralization of 
the osteoid tissue process. Its main function is to produce bone matrix during the 
development or repair of bone tissue, which means it is responsible for bone formation.8 
  
The osteocytes are flat and spindle-shaped cells that support the bone and are located 
inside the lamellas of cancellous and compact bone. These cells are completely 
surrounded by extracellular matrix, forming a space called gaps. The amount of bone 
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osteocytes existent per bone volume unit is directly dependent on the speed of the tissue 
forming process, i.e. the higher the speed of the formation of bone osteoblasts the 
greater will be the amount of osteoblasts that will later become osteocytes. Thus it can 
be said that their function includes bone formation (by osteoblasts), maintenance of the 
matrix and calcium homeostasis.8 
  
Osteoclasts are cells that are different from others because they have higher volume and 
multiple cores. These cells play a crucial role in bone resorption and removal process 
(remodel the bone to reduce its volume) through chemical or enzymatic action. Thus, the 
bone is destroyed, releasing calcium or in conjunction with the process of bone 
deposition, leading to the remodelling of the tissue as a result of functional requirements. 
In addition to osteolytic functions, osteoclasts play a major role in the bone development 
and growth, through the release of polypeptide-like growth factors from the mineralized 
extracellular matrix.8 
 
Finally, the undifferentiated mesenchymal cells are located in the conjunctive tissue 
between the trabeculae, throughout the vascular channels, and in the periosteum. Its 
main function is to differentiate into osteoblasts.8 
 
At the molecular level, the bone comprises a bone matrix of lamellar or non-lamellar 
bone. The bone matrix is where the cells are located. The bone matrix is composed of 
organic and inorganic matter. The inorganic or mineral portion (approximately 70%) is 
mainly composed of small HA crystals. The organic phase is composed of Type I collagen 
fibres embedded in a homogeneous substance containing glycoproteins and 
proteoglycans.8 
 
2.1.3. Bone Formation and Osteoconduction  
 
Osteoconduction is critical to osteogenesis during the remodelling process in normal 
bone and consists of three main processes: 
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- Migration of progenitor cells of the bone via a transient matrix; 
- Bone progenitor cell differentiation; 
- Functional differentiated cells recruitment to initiate new bone formation.11 
Osteogenesis is the result of osteoconduction and bone formation, occurring when the 
bone’s first layer is directly secreted into the surface of the implant. During 
osteoconduction, pre-osteogenic cells are stimulated to migrate through a provisional 
matrix which can be represented by bone grafts, implant, or a blood clot. The migrating 
cells then begin a process of differentiation which results in the secretion of the new 
bone matrix. 12 
During bone formation, differentiated osteogenic cell secrete globular increases of a 
matrix devoid of collagen, called sealer. These afibrillar layers are located in the 
secondary osteons interface with surrounding tissue, and can also be seen in the bone-
implant interface. This first layer provides nucleation sites for calcium phosphate nano-
crystals which go through nucleation and growth inside the organic matrix. After 
deposition of the cement line matrix, the osteogenic cells differentiate into osteoblasts 
that produce extracellular collagen matrix as fibres. Finally, collagen fibres go through 
calcification and are separated from the underlying substrate by a calcified matrix without 
collagen.12 
 
2.1.4. Bone Growth and Modelling  
 
The bone undergoes longitudinal and radial growth, modelling and remodelling 
throughout life. The longitudinal and radial bone growth occurs during childhood and 
adolescence. The longitudinal growth occurs in the growth plates, where the cartilage 
proliferates in epiphyseal and metaphyseal areas of long bones, before subsequently 
being subjected to mineralization to form new primary bone.13 
Bone modelling is the process by which bones change its overall shape in response to 
physiological influences or mechanical forces, leading to a gradual adjustment of the 
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skeleton in response to forces that are exerted. Bones may extend or modify the shaft by 
removing or adding bone to the appropriate surfaces, by the independent action of 
osteoblasts and osteoclasts in response to biomechanical forces. Bones typically extend 
with aging in response to periosteal apposition of new bone and endosteal resorption of 
old bone (native). Wolff's law describes the observation that long bones change shape in 
order to accommodate the stresses placed upon them. In adults, bone modelling is less 
frequent than remodelling.13 
 
2.1.5. Bone Remodelling 
 
Bone remodelling is the process by which bone is renewed to maintain bone strength and 
mineral homeostasis. Remodelling involves the continuous removal of discrete portions 
of old bone, its replacement with newly synthesized protein matrix and subsequent 
mineralization of matrix to form new bone.7 
The remodelling process resorbs old bone and forms new bone to prevent the 
accumulation of bone micro injuries. Remodelling begins before birth and continues until 
death. The bone remodelling unit is composed of a tightly coupled group of osteoclasts 
and osteoblasts that sequentially perform the resorption of old bone and formation of 
new bone. Bone remodelling increases with age, especially along the perimenopause and 
post menopause. The remodelling cycle consists of four sequential steps: activation, 
resorption, formation and reversion, as represented in Figure 2. The remodelling sites 
may be developed randomly, but are also targeted to areas that require repair.7 
The activation involves the recruitment and activation of monocyte-macrophage 
mononuclear osteoclasts precursors, of the circulation, endosteal elevation containing 
the lining cells of the bone surface and fusion of various mononuclear cells to form 
multinucleated pre-osteoclasts. These bind to bone matrix through interactions between 
the integrin receptor on their cell membranes and peptides containing RGD (arginine, 
glycine and asparagine) in matrix proteins.7 
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Figure 2 – Scheme of normal bone remodelling cycle (Adapted from Clark B. 7). 
 
During the reversion phase, bone resorption transits to bone formation. At the end of 
bone resorption, the resorption cavities contain a variety of mononuclear cells, including 
monocytes, osteocytes released from the bone matrix, and pre-osteoblasts recruited to 
start the formation of new bone, on which also participate various growth factors.7 
Bone formation lasts from 4 to 6 months. Osteoblasts synthesize new collagenous organic 
matrix and regulate the mineralization of the matrix, releasing small membrane-bound 
matrix vesicles that concentrate calcium and phosphate and enzymatically destroy 
mineralization inhibitors, such as proteoglycans or pyrophosphate.7 
Osteoblasts, located within the matrix become osteocytes with an extensive canaliculi 
network that connects it to the lining cells on the bone surface, to the osteoblasts and 
other osteocytes, held by gap junctions. The end result of each bone remodelling cycle is 
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the production of a new osteon. The main functions of bone remodelling include the 
preservation of the bone mechanical strength, replacing old bone with micro injuries by 
new bone, healthier and with calcium and phosphate homeostasis.7 
 
2.2. Biomaterials for bone regeneration 
 
Knowing the response of tissues in contact with a biomaterial is fundamental at the time 
of proceeding to the choice of  a material to use in an implant.14 Successful 
implementation of a biomaterial in the body depends mainly on two factors:  
Biofunctionality, which is directly related to the biomaterial's ability to perform a 
particular function (or part of it) of the body.14 
Biocompatibility, which is based on the analysis of the reactions occurred on the surface 
of the implant, not only at the time of implementation, but also over time when it 
undergoes a process of degradation and wear. Thus, in terms of biological response, after 
implanting a biomaterial a formation of a hematoma can occur, with an inflammatory-like 
response and the call  of water and glycoproteins, which overlays and adhere to the 
implant.14 
  
In general, biomaterials can be classified in two ways: its chemical composition and its 
biological behaviour.15 Regarding chemical composition, biomaterials can be divided into 
4 classes:  
- Metals and metal alloys; 
  - Ceramic; 
  - Polymers; 
  - Composites. 
The classification of biomaterials, considering their biological behaviour, is based on the 
host tissue response. Thus, biomaterials can be classified as: 
 - Bioinert - Do not cause the body's reaction to a foreign body, lying in direct 
connection to the host tissue (e.g. titanium, zirconia and alumina); 
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 - Biotolerant - are moderately accepted by the host tissue, usually surrounded by 
a fibrous capsule (for example, stainless steel, cobalt-chromium alloys and poly(methyl 
methacrylate) (PMMA)).15 
 
2.2.1. Bioglasses (BG) 
 
In 1969 Larry Hench and co-workers successfully produced the first BG, being therefore 
considered the pioneers in the use of bioactive glasses for biomedical purposes.5 The 
main feature of the BG is the ability to promote a rapid and durable chemical bond 
through an apatitic interface with bone tissue.15 The traditional method of production of 
a glass by thermal fusion followed by cooling to solidify without crystallization, has 
proved to be limiting for some chemical compositions BGs, so the preparation by the sol-
gel has been most commonly used for these cases.15 The composition of BGs is essentially 
based on silica (silicate glasses) or phosphorus (phosphorus glasses), depending on the 
glass former used. These last are more easily melted and chemically more unstable than 
the silicate. The presence of phosphate groups (PO43) associated with calcium (Ca2+) in 
the bone tissue is of great importance. The ability of a BG to bind to bone, undergo 
biodegradation and form an apatite surface layer varies depending on the composition 
and ratio of its components.15 
 Despite the successful use of BGs as bone graft substitutes, recent studies found 
high basicity of BG 45S5 when placed in contact with a mean, PBS or biological tissue. 
Thus, the surface of BG 45S5 becomes extremely reactive, leading to fast degradation 
rates in vitro and in vivo and poorer mechanical strength, which may not coincide with 
the growth rate of new bone. This limitation can compromise bone regeneration in 
defects, therefore new BG compositions have emerged, like the FastOs, which is 
biocompatible, osteoconductive and promotes osseointegration, and has the particularity 
of being resorbed more slowly than BG 45S5, making it a potential candidate for bone 
regeneration. This BG is characterized by having excellent in vitro properties when 
cultured with mesenchymal stem cells, like high biomineralization rate, a more 
hydrophilic character and a higher modulus of elasticity.16 FastOsBG also has an 
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excellent densification capability, being possible to obtain very dense and sintered 
materials but amorphous, with flexural resistance of 85 MPa after sintering for 1 h at 800 
°C.16 All these features make FastOsBG a strong candidate for incorporation into 
bioactive systems. 
 
2.2.1.1. BG synthesis by melt-quenching 
 
A glass can be produced by two processing methods: the traditional melt-quenching 
method and sol-gel. BG 45S5® and other commercial bioactive glasses are produced by 
the traditional method, in which the oxides are melted together at elevated temperatures 
(above 1300 °C) in a platinum crucible and cooled immediately (quenching) in a graphite 
mould or water to obtain a frit. These two methods of synthesis provide different physical 
properties to the BGs. The BGs prepared by sol-gel tend to have an inherent nano-
porosity, while the BGs prepared by melt-quenching are dense.17 FastOsBG can be 
prepared by melt-quenching in platinum crucibles to 1570 °C. Then, the BG is poured into 
cold water to obtain a frit. The frit is firstly dried and then milled in a high energy mill to 
obtain the suitable particle size distribution.16 
 
2.2.2. Calcium Phosphates (CaP) 
 
The mineral part of normal bone and teeth consists essentially of carbonated 
hydroxyapatite deficient in calcium (Ca/P <1.67). This explains why a huge variety of bone 
substitutes is made from biphasic calcium phosphates consisting of hydroxyapatite (Ca/P 
= 1.67) and β-TCP (Ca/P = 1.5). Being bioactive and osteoconductive materials, they are 
distinguished by a strong organic bond that allows the growth and proliferation of the 
bone to the implant. β-TCP is biodegradable, and as it is resorbed, allows bone ingrowth 
up to full substitution of the implant. The most important property of CaP is probably its 
solubility in water due to the fact that the in vivo behaviour of the CaPs can be predicted 
by its solubility. Thus, according to solubility, CaPs can be ranked by decreasing order of 
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degradation rate in situ (pH 7.0)18: α-TCP> DCPD> OCP> β-TCP> HA19. The main calcium 
phosphates used for tissue regeneration are shown in Table 1.  
 
Table 1 – Calcium phosphates frequently used for tissue regeneration (Adapted from Dorozhkin 
SV. 10). 
Ca/P Molar 
Ratio 
Compound Mineral Formula 
1.0 
Dicalcium Phosphate 
anhydrous (DCPA) 
Monetite CaHPO4 
1.0 
Dicalcium Phosphate 
dihydrate (DCPD) 
Brushite CaHPO4.2H2O 
1.33 
Octacalcium Phosphate 
(OCP) 
- Ca8(HPO4)2(PO4)4.5H2O 
1.43 - Whitlockite Ca10(HPO4)(PO4)6 
1.5 Tricalcium Phosphate - 
α-Ca3(PO4)2 
β-Ca3(PO4)2 
1.67 - 
Hydroxyapatite 
(HA) 
Ca10(PO4)6(OH)2 
2.0 Tetracalcium Phosphate - Ca4P2O9 
 
Commercial CaP biomaterials are available in different forms, e.g: beads, plates, coatings 
or cements.20 The CaP granules are used to fill bone defects for the purpose of helping 
bone regeneration, without any structural support. CaP hard blocks can be used to fill 
bone defects with a defined geometric shape, supporting higher loads. For more complex 
bone defects, customised implants can be made by measuring the volume of the lesion, 
and producing the part by using additive manufacturing methods such as 3D printing or 
Robocasting. Given the advantageous biological properties of CaP coatings, these are 
applied in many metallic implants used in the bone to promote bone growth around 
implants.20 
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2.2.2.1. Tricalcium Phosphate (TCP) 
 
Tricalcium phosphate can exist in two allotropic forms, β-TCP and α-TCP. Even in pure 
stoichiometric composition (Ca/P = 1.5), the β-TCP phase is only formed through heat 
treatment at  800 °C temperatures, being thermally stable until up to temperatures of  
1125 °C. Above this temperature, β-TCP is transformed gradually into the high-
temperature phase, α-TCP, transformation that occurs with a volumetric expansion 
(increase of network parameters).12 Both phases are resorbable, being the resorption rate 
of α-TCP faster than that of β-TCP. The resorption rate depends on the solubility, which 
determines the surface concentration of calcium and phosphorus available to stimulate 
phenotypic differentiation of osteogenic cells, initiating mineralization, leaving free space 
to promote osseointegration.20 The degradation occurs through osteoclast activity. The 
main disadvantages of the TCP, when compared to HA, are related to the lack of 
structural support caused by its too fast resorption, because of its greater solubility, 
especially when associated with macroporosity.20  
The use of biphasic calcium phosphate (BCP = β-TCP + HA) is also a common strategy to 
regulate the rate of resorption and adjust it to the growth rate of new bone.10 
The biodegradability makes these bioceramics very attractive as bone substitutes, as it 
can present in different forms (granules, porous blocks, or mouldable / Injectable pastes). 
In the form of powder slurry, they are less effective due to its lack of macro porosity 
necessary for bone ingrowth. If it’s combined with additives such as naphthalene or 
starch (porogens) it is possible to obtain macropores in a range of 100 to 300 microns, 
and consequent interconnectivity which provides faster osseointegration.10 The granular 
shape is the most efficient of the three (granular, macroporous and gels) because the 
spaces between the beads increase the porosity of the matrix as well as its contact 
surface. Nevertheless, it presents an injectability problem, making it difficult to be formed 
into a 3D structure. 
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2.2.2.1.1. β-TCP powder synthesis 
 
The synthesis of TCP high purity powders is not reported in the literature when compared 
to the HA. This can be accomplished using two methods: solid state reactions at high 
temperature or by precipitation at a low temperature, followed by calcination. The main 
problem of both methods relies on the variability of the composition of the powders.21 
The solid state reactions at high temperatures are hardly used for the synthesis of large 
quantities because of the difficulty in controlling the intimate mixture of reagents 
powders and the complete reaction between them.21 Thus, the preparation of 
stoichiometric final products without second phases waste often requires successive 
grindings and/or corrections in the stoichiometry followed by sintering. Considering the 
wet methods, the β-TCP cannot be directly synthesized in aqueous solution. 
The compound which is able to precipitate is apatitic tricalcium phosphate 
Ca9(HPO4)(PO4)5(OH), which seems to be hydroxyapatite Ca10(PO4)6(OH)2, where one ion 
an HPO42 replaces PO43. The β-TCP anhydrous crystallization requires calcination of the 
apatitic compound at temperatures above 750 °C. The apatitic TCP synthesis is 
conceivable through the aqueous routes classically used for the synthesis of 
stoichiometric HA. The non-stoichiometric apatites Ca10-x (HPO4)x(PO4)6-x(OH)2-x with 0 ≤ x 
≤ 1 can be precipitated, with the value of x dependent on the synthesis conditions.21 
 The most important parameters to control are the pH and temperature. Although the 
values reported in the literature are widely dispersed, a pH value maintained near 
neutral, slightly acidic, and low temperatures are generally used. The kinetics of 
precipitates formation is still little understood and the maturation times after total 
addition of reagents vary depending on the lack of maturity up to 12 h.21 
Pure β-TCP is formed after calcining the powder with Ca/P = 1.500. For Ca/P values 
greater than 1.500, HA is formed as a second phase. A relative variation of 1% of the Ca/P 
molar ratio induces the formation of 10 wt % of HA. For Ca/P values smaller than 1.500 is 
formed another second phase: calcium pyrophosphate Ca2P2O7. The biological and 
mechanical properties of calcium phosphate compounds strongly depend on its chemical 
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composition. Consequently, its preparation must be highly controlled to obtain 
reproducible properties and should be used accurate characterization techniques, such as 
the analysis of X-ray diffraction (XRD), infrared (FTIR) and scanning electron microscopy 
(SEM).21 
 
2.2.3. Injectable bone substitutes 
 
The discovery of calcium phosphate cements (CPC) in 1982 and 1983 marked a new era in 
which the handling properties of bone substitutes became extremely important.9,22 
Continued research efforts are reflected in a rapid increase in the number of publications. 
For example, when performing a search on "Scopus" (www.scopus.com) using the two 
keywords "Injectable" and "Ceramic" is verified that almost 750 articles were published in 
2015 (Figure 3).  
 
Figure 3 – Number of articles cited per year in scopus (www.scopus.com) when selecting the 
following keywords (search in all fields): (green) “Injectable” and “Ceramic”; (red) “Putty” and 
“Ceramic”. 
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Over the last 15 years, a large variety of ceramic cements have been commercially 
introduced in the market as bone substitutes. Consequently, it is necessary to better 
understand the specific properties of these biomaterials, such as injectability, cohesion, 
setting time, and properties in vitro and in vivo.23 There is a great diversity of new 
approaches proposed to improve them (Table 2).23 
Table 2 – List of commercially available ceramic cements. The main end product of the reaction 
can be either an apatite (calcium deficient, carbonate, among others), brushite (DCPD) or gypsum 
(CaSO4 • 2 H2O) (Adapted from Bohner M. 23). 
Producer 
Product 
name 
Composition Product 
AG Digital 
Technology Corp 
A-GRIX 
Powder: calcium sulphate 
hemihydrate powder (CaSO4.1/2 H2O; 
CSH) & calcium sulphate granules; 
Solution: Aqueous solution 
Gypsum 
Berkeley Advanced 
Biomaterials (US) 
Cem-
Ostetic™ 
Powder: calcium phosphates (details 
unknown); Solution: Sterile water 
Apatite 
Tri-Ostetic™ Powder: calcium phosphates (details 
unknown); Solution: Sterile water 
Apatite 
Biocomposites Ltd 
(GB) 
Genex® Composition: could not be found Gypsum 
Biomatlante (FR) MCPC 
Powder: mainly α-TCP, ACP, BCP = 
biphasic calcium phosphate 
(composite between HA 
and β-TCP); Solution: phosphate 
buffered solution (Khairoun et al., 
2005) 
Apatite 
 
 
 
 
 
 
 
Biomet (US) 
Interpore (US) 
Calcibon® 
Powder: α-TCP (61%), DCP (26%), 
CaCO3 (10%), PHA (3%); Solution: 
H2O, Na2HPO4 
(Khairoun et al., 1999) 
Apatite 
Mimix™ 
Powder: TetCP, α-TCP, trisodium 
citrate (C6H5O7Na3·2H2O); Solution: 
H2O, citric acid 
(C6H8O7) 
 
Apatite 
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Walter Lorenz 
Surgical (GER) 
Quick Set 
Mimix™ 
Powder: Calcium phosphate powders, 
Na3C6H5O7·2H2O; Solution: Citric 
acid aqueous solution 
Apatite 
Bone Plast® 
QS 
Powder: CSH (CaSO4·½H2O); Solution: 
sterile aqueous solution 
Gypsum 
BoneSupport AB 
(SWE) 
Cerament™ 
Powder: CaSO4·½H2O (60%), HA 
(40%); Solution: Aqueous solution of 
an iodine 
radiopacifier 
(http://www.bonesupport.com/) 
Gypsum 
Calcitec (US) Osteofix 
Powder: calcium phosphate and 
calcium oxide powders; Solution: 
phosphate buffer 
Apatite 
ETEX (US) 
? -BSM; 
Embarc; 
Biobon 
Powder: ACP (50%), DCPD (50%); 
Solution: Unbuffered aqueous saline 
solution (Lee et al., 
1999; Tofighi et al., 2001) 
Apatite 
β-BSM 
Composition: could not be found (it 
has apparently a higher compressive 
strength and better injectability than 
α-BSM) 
Apatite 
γ-BSM Composition: could not be found 
(“putty” consistency) 
Apatite 
OssiPro 
Composition: could not be found; The 
cement is claimed to be macroporous 
after hardening 
Apatite 
CarriGen 
Composition: synthetic calcium 
phosphate, sodium carboxymethyl 
cellulose, sodium 
bicarbonate, and sodium carbonate 
Apatite 
Futura Biomedical 
(US) 
OsteoCure Powder: CaSO4·½H2O; Solution: 
sterile mixing solution 
Gypsum 
Graftys (FR) 
Graftys® HBS 
Powder: mainly ? -TCP, ACP, BCP = 
biphasic calcium phosphate 
(composite between HA 
and β-TCP); Solution: phosphate 
buffered solution (Khairoun et al., 
2005) 
Apatite 
Graftys® 
Quickset 
Composition: calcium phosphate salts, 
hydroxypropylmethylcellulose 
(HPMC), and 
phosphate-based aqueous solution 
Apatite 
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Kasios (FR) 
Jectos 
Eurobone® 
Powder: β-TCP (98%), Na4P2O7 (2%); 
Solution: H2O, H3PO4 (3.0M), H2SO4 
(0.1M) 
(Frayssinet et al., 2000) 
Brushite 
Jectos+ 
Composition: could not be found 
(likely to be close to that of Jectos) 
(http://www.kasios.com/doc-
pdf/JECTOS%2B699ed03-frgb.pdf) 
Brushite 
Kyphon (US) KyphOs™ 
Powder: ? -TCP (77%), Mg3(PO4)2 
(14%), MgHPO4 (4.8%), SrCO3 (3.6%) ; 
Solution: H2O, 
(NH4)2HPO4 (3.5M) (Mulliez and 
Wenz, 2002) 
Apatite 
Lifecore (US) CalMatrix 
Powder: 90% CaSO4·½H2O and 10% 
carboxymethylcellulose; Solution: 
could not be found 
Gypsum 
Mitsubishi Materials 
(J) 
Biopex® 
Powder: α-TCP (75%), TetCP (20-18%), 
DCPD (5%), HA (0-2%) 
Solution: H2O, Sodium succinate (12-
13%), sodium chondroitin sulfate (5-
5.4%) (when two values are indicated, 
the first value stems from reference 
(Kurashina et al., 1997) and the 
second value from reference (Tanaka 
et al., 2003)) 
Apatite 
Biopex®-R 
Powder: α-TCP, TetCP, DCPD, HA, 
Mg3(PO4)2, NaHSO3 
Solution: H2O, Sodium succinate, 
sodium chondroitin sulfate (Tanaka et 
al., 2003) 
Apatite 
Orthogen 
Corporation 
DentoGen 
CSH powder and aqueous solution 
Gypsum 
Produits Dentaires SA 
(CH) 
CalciphOs (CH) 
VitalOs4 
Solution 1: β-TCP (1.34g), Na2H2P2O7 
(0.025g), H2O, salts (0.05M pH 7.4 
PBS solution); 
Solution 2: MCPM (0.78g), 
CaSO4·2H2O (0.39g), H2O, H3PO4 
(0.05M) (Brendlen et al., 
2003) 
Brushite 
Shanghai Rebone 
Biomaterials Co (CN) 
Rebone Powder: TetCP, DCP; Solution: H2O 
(Liu et al., 1997) 
Apatite 
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Skeletal Kinetics (US) 
Callos™ 
Composition: α-TCP, CaCO3, MCPM; 
Solution: sodium silicate(Constantz, 
2002) 
Apatite 
Callos 
Inject™ 
Composition: α-tricalcium phosphate 
and unknown compounds (likely to be 
close to that of Callos™) 
Apatite 
OsteoVation 
EX 
Inject 
Probably similar to “Callos Inject™” 
(Product produced by S.K. but sold by 
OsteoMed) 
Apatite 
Stryker (US) 
 BoneSource 
Powder: TetCP (73%), DCPD (27%); 
Solution: H2O, mixture of Na2HPO4 
and NaH2PO4 
(Brown and Chow, 1985; Brown and 
Chow, 1983; Chow, 1991) 
Apatite 
Leibinger (GER) HydroSet™ 
Powder: TetCP, DCPD, trisodium 
citrate; Solution: H2O, 
polyvynilpyrrolidone, sodium 
phosphate (Hannink et al., 2008) 
Apatite 
Synthes (US) 
Norian® SRS 
Norian® CRS 
Powder: α-TCP (85%), CaCO3 (12%) 
MCPM (3%); Solution: H2O, Na2HPO4 
(Constantz et 
al., 1995; Fernandez et al., 1998) 
Apatite 
Norian® SRS 
Fast Set 
Putty 
Norian® CRS 
Fast Set 
Putty 
Composition: could not be found 
(likely to be close to that of Norian 
SRS/CRS) 
Apatite 
Norian 
Drillable 
Composition: calcium phosphate 
powder, bioresorbable fibers and 
sodium hyaluronate 
solution 
Apatite 
chronOS™ 
Inject 
Powder: β-TCP (73%), MCPM (21%), 
MgHPO4·3H2O (5%), MgSO4 (<1%), 
Na2H2P2O7 
(<1%); Solution: H2O, sodium 
hyaluronate (0.5%) (Bohner et al., 
2003) 
Brushite 
 
 
Teknimed (FR) 
Cementek® 
Powder: α-TCP, TetCP, Na 
Glycerophosphate; Solution: H2O, 
Ca(OH)2, H3PO4 (S. 
Goncalves, Teknimed, private 
communication) 
 
Apatite 
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Cementek® 
LV 
Powder: α-TCP, TetCP, Na 
Glycerophosphate, dimethylsiloxane; 
Solution: H2O, Ca(OH)2, 
H3PO4 (S. Goncalves, Teknimed, 
private communication) 
Apatite 
Wright Medical (US) 
MIIG™ 115 Powder: CSH; Solution: Saline (Turner 
et al., 2003) 
Gypsum 
MIIG® X3 
Composition: CSH; Solution: Sterile 
water (contains also traces of an 
accelerant) 
Gypsum 
MIIG® X3 
High- 
Visc 
Composition: CSH; Solution: Sterile 
water (less than in MIIG® X3; contains 
also traces of an 
accelerant) 
Gypsum 
Pro-Dense® 
Composition: 75% CSH, 25% brushite 
and granular β-TCP 
Gypsum 
 
Combining the keyword "Putty" and "Ceramic" a smaller number of publications is 
obtained, but the development is remarkably similar.23 Recently, attention shifted to 
hydrogels composites and bone substitutes, resulting in the discovery and 
commercialization of various products (Table 3).  
Table 3 – List of some non-setting non-allogenic pastes with indication of producer, product name, 
composition and form (pre-mixed or to be mixed). Denominations: BCP = biphasic calcium 
phosphate (composite between HA and β-TCP); CMC = carboxymethylcellulose; HPMC: 
hydroxypropylmethylcellulose (Adapted from Bohner M. 23). 
Producer Product name Composition Form 
ApaTech (UK) 
Actifuse™ HA, polymer and aqueous solution Pre-mixed 
Actifuse™ Shape 
Actifuse™ ABX 
Silicon-substituted calcium 
phosphate and polymer 
Pre-mixed 
Baxter (US) 
TricOs T 
TricOs 
BCP (60% HA, 40% β-TCP) granules 
and Tissucol 
(fibrin glue) 
To be 
mixed 
Berkeley 
Advanced 
Biomaterials 
Bi-Ostetic Putty Non-disclosed 
Not 
disclosed 
BioForm (US) 
“Calcium 
hydroxylapatite 
implant” 
HA powder embedded in a mixture 
of glycerine, water, 
and CMC1 
Pre-mixed 
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Biomatlante 
(FR) 
MBCP Gel® 
BCP granules (60% HA, 40% β-TCP; 
0.08-0.2mm) and 2% HPMC (Boix 
et al., 2006; Gauthier et al., 2005) 
Pre-mixed 
Hydr’Os 
BCP granules (60% HA, 40% β-TCP; 
micro and 
nanoparticles) and saline solution 
(Biomatlante, private 
communication) 
Pre-mixed 
Degradable 
solutions (CH) 
easy graft™ 
β-TCP or BCP granules (0.45-
1.00mm) coated with 10 μm PLGA, 
N-methyl-2-pyrrolydone (K. 
Ruffieux, 
private communication) 
To be 
mixed 
Dentsply (US) Pepgen P-15® flow 
Hydroxyapatite (0.25-0.42mm), P-
15 peptide and 
aqueous sodium hyaluronate 
solution (product brochure) 
To be 
mixed 
DePuy Spine 
(US) 
Healos® Fx HA (20-30%) and collagen 
To be 
mixed 
Fluidinova (P) 
nanoXIM TCP β-TCP (5 or 15%) and water 
(company website) 
Pre-mixed 
nanoXIM HA HA (5, 15, 30, or 40%) and water 
(company website) 
Pre-mixed 
Integra 
LifeSciences 
(US) 
Mozaik 
Osteoconductive 
Scaffold 
β-TCP (80%) and type 1 collagen 
(20%) 
To be 
mixed 
Mathys Ltd 
(CH) 
Ceros® Putty / 
cyclOS® Putty 
β-TCP granules (0.125-0.71mm; 
94%) and recombinant sodium 
hyaluronate powder (6%) 
To be 
mixed 
Medtronic (US) Mastergraft® BCP (85% HA, 15% β-TCP) and 
bovine collagen 
To be 
mixed 
NovaBone (US) NovaBone® Putty Bioglass and synthetic binder Pre-mixed 
Orthovita (US) 
Vitoss Flow 
Contains at least bioactive glass 
and saline solution (or blood 
marrow aspirate, or blood) 
To be 
mixed 
Vitoss Pack 
Contains at least bioactive glass 
and saline solution (or blood 
marrow aspirate, or blood) 
To be 
mixed 
Osartis / AAP 
(GER) 
Ostim® Nanocrystalline HA (35%) and 
water (65%) (Laschke et al., 2007) 
Pre-mixed 
 JAX CS CSD granules and an aqueous 
solution 
To be 
mixed 
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Smith & 
Nephew (US) 
(http://global.smithnephew. 
com/us/JAX_CS_OVERVIEW_7221.
htm) 
JAX TCP 
β-TCP granules and an aqueous 
solution of 1.75% CMC and 10% 
glycerol (Clarke et al., 2007) 
To be 
mixed 
Stryker (US) Calstrux™ β-TCP granules and CMC 
To be 
mixed 
Teknimed (FR) Nanogel 
Nanocrystalline HA (100-200nm) 
(30%) and water (70%) (S. 
Goncalves, private 
communication) 
Pre-mixed 
Therics (US) Therigraft™ Putty β-TCP granules and polymer Pre-mixed 
Zimmer (US) Collagraft 
BCP granules (65% HA, 35% β-TCP; 
0.5-1.0 mm), bovine collagen, and 
bone marrow aspirate (Bucholz, 
2002) 
To be 
mixed 
 
Injectability describes how easy or difficult it is to inject a bioactive system from a 
syringe24, being a very relevant property in minimally invasive surgical procedures in the 
area of orthopaedics and dentistry. Some authors define injectability of a paste as its 
ability to remain homogeneous during its injection.24 
In other words, the paste must be able to be extruded through a needle without the 
occurrence of solid/liquid (S/L) phase separation. To this end, one of the crucial aspects 
that must be taken into account is the cohesion of the paste, because a CPC with ideal 
cohesion hardens even in contact with fluids without disintegrating and without phase 
separation during the injection of the product.25 Another aspect, perhaps the most 
important one, is the study of the rheological behaviour, i.e., how the paste flows under 
the action of applied stresses. For a CPC paste to be injectable it should have relatively 
low viscosity in order to offer little resistance when it is leaving the syringe. However, the 
more viscous formulations are useful in situations where the surgeon chooses to 
manually place the paste in the place.26 
There are several aspects that should be taken into account regarding the improvement 
of the rheological behaviour of bone cements. The first can be the injection apparatus 
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itself, since shorter cannulas and with a larger diameter favour the flow of the cement. 
The proportion between the solid and liquid phases is another relevant aspect to 
consider. The paste becomes less viscous with increasing the proportion of liquid and 
might therefore be easier to inject. This may have consequences related to mechanical 
properties, as well as lead to the annihilation of the paste’s cohesion.19 Another 
important aspect relates to the adjustment of size and size distribution of the particles of 
CPC components. Thinner particles pass better through narrower needles, but require a 
higher amount of liquid, which decreases the cohesion of the paste and leads to higher 
porosity and, also, worse mechanical properties.19 
Another practical key aspect for all implantable materials is the expiration date after 
preparation. This describes how long an injectable cement can be stored with their 
properties intact. In a recent study27 using dry powder mixtures of β-TCP, it was found 
that the powders tended to react with moisture in the surrounding atmosphere to form 
monetite. It was found that storage in dry atmosphere (argon), at low temperatures and 
the addition of retardants would help prolong the shelf life for the powder mixtures 28. 
When the CPCs are stored in sealed syringes, the total amount of water present in the 
cement will be decisive for its validity.24 
The size and distribution of sizes of the particles/agglomerates represent properties of 
extreme importance in all current bioactive systems. The flow behaviour is strongly 
dependent on these characteristics. The viscosity of the liquid is also of great importance. 
The flow behaviour is generally improved when the viscosity of the liquid increases, 
because a higher viscosity inhibits the segregation of the particles and the filter pressing 
effect.23 
The final product characteristics can vary depending on the composition of the phases, 
the S/L ratio, the calcium/phosphorus (Ca/P) molar ratio and the presence of additives. 
Therefore, the properties of the cement such as the initial plasticity, time of 
cohesion/consolidation and of hardening must be taken into account, as well as the final 
mechanical resistance and injectability.27 
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2.2.3.1 Calcium Phosphate Cements (CPC)  
 
The first cements based on calcium phosphates (CPC) could be shaped in any way, and it 
would make the utilization of CaP as bone substitutes easier.29 The first publications 
reported on the use of CPC in dental cavity filling, where its superior biocompatibility and 
absorption reportedly enabled the best results. Today, the use of CPC in dentistry is 
limited since they do not have the mechanical properties required for repair of the cavity. 
Still, there are various applications of these biomaterials in orthopaedics, maxillofacial 
surgery and bone defects filling in general.29 
Reactive CPCs pastes are malleable for a certain period of time, allowing the surgeon an 
easy accommodation in the bone defect with his own hands. Moreover, CPCs pastes can 
be placed in syringes and injected directly into bone defects in minimally invasive 
surgeries, preventing infections and reducing patient recovery time. These handling 
facilities confer to CPCs great advantages when compared to other non-malleable 
shapes.29 These injectable systems need to be prepared (mixed) before application and 
meet a number of key aspects summarised in in Table 4. 
 
Table 4  – Important properties for injectable calcium phosphate cement and the questions to be 
investigated in this thesis (Adapted from Aberg J. et al 30). 
Stage Property Question to answer 
Handling 
(before injection) 
Working time 
- How much time does the 
surgeon dispose for 
injection? 
 
Injectability 
 
- Is the cement easy or 
difficult to inject? 
 
 
 
Hardening 
(0-24 h after Injection) 
 
Setting time 
 
- How long time before the 
patient can be moved? 
 
Final phase composition 
 
- What chemistry will the 
biology encounter? 
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Mechanical properties 
- How strong is the 
cement? 
- For what applications can 
it be used? 
Biology 
(0-12 weeks, post 
implantation) 
 
In vitro 
 
- What is the cellular 
response? 
In vivo 
- Will the cement be 
resorbed? 
- Can bone grow onto the 
cement? 
Shelf life ̶ 
- For how long can the 
cement be stored? 
  
The development of the fundamental properties of CPCs for biomedical applications can 
be divided into the three stages indicated in Table 4. The first stage refers to properties 
that are important before the cement is inside the body24. The second phase begins 
immediately after injection and continues until the complete hardening of the cement. 
Thereafter, the immediate and long term biological response is discussed in the third 
stage. Finally, the shelf life of cement is equally an important aspect, although it is not 
directly a part of the surgical procedure.24 
In a clinical situation, the time that the surgeon has to prepare and inject the cement in a 
bone defect is designated working time (WT). Conventionally, the WT is measured using 
two methods: the Gilmore’s needle method or the Vicat needle. The first Gilmore needle 
weighs 113.4 g and has a tip diameter of 2.12 mm. It is placed on the surface of the 
cement paste and the depth of its printing is registered. When the needle leaves no 
visible impression on the cement, it is considered that its WT was achieved, also called 
initial setting time. The same method is also used to measure the final setting time using 
the second Gilmore needle that weighs 453.6 and has a tip diameter of 1.06 mm 24. The 
sequence of events along the cement setting is schematised in Figure 4. Additives are 
commonly used method to control the setting kinetics and the rheological properties of 
CPC 24.  
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Figure 4 – Setting time scheme (Adapted from Driessens FCM. et al 31). 
 
After applying the Gilmore needle method, the initial setting time (IST) and final setting 
time (FST) values are obtained. However, there is still no consensus on what should be 
the ideal values of IST and FST, and its clinical meaning. Some researchers have suggested 
that cement should be injected before the IST, while the wound must be closed and after 
FST, making sure that the cement has not suffered deformation between these two 
periods.31  
For Ginebra32 the clinical meaning of these times is that the paste should be implemented 
before the IST and the wound can be closed after the FST. The cement should not be 
deformed in the solidification period between IST and FST because any deformation may 
induce cracks in it. That said, the period between IST and FST should be the time that the 
material takes to solidify until it becomes a material strong enough to withstand a certain 
pressure without deforming or breaking. The three requirements for the proper handling 
of the CPC, with numbers expressed in minutes (min), are presented below. 
 
3 ≤ IST < 8 (I) 
IST – CT ≥ 1 (II) 
FST ≤ 15 (III) 
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The requirement (II) means that the cohesion time (CT) should occur at least one minute 
before the IST, so the doctor has at least one minute to apply and shape the material. 
Since the mixing of the components takes about 1 min, the shorter CT that is permitted is 
only two min. Therefore the doctor has at least a minute to remove the paste from the 
spot where the mixing is carried out, putting it on the spatula or syringe in which the 
placement of CPC in the bone defect site will be effected. This should occur after CT and 
before IST. Alternatively, the doctor may also apply the CPC directly with his hands, 
shaping it with his fingers until the desired shape for use is achieved, as long as that 
implementation takes place also between CT and IST. For dental applications, the IST 
should be close to 3 min, while for orthopaedic applications it should be close to 8 min. 
Finally, the FST cannot exceed 15 min.32 
The use of CPC as an injectable system can make the process longstanding, since the CPC 
is prepared in full operation by the clinician. After making the mixture it is necessary to 
transfer the paste to the syringe, which can take some time. In this case, it may be 
desirable that the initial setting time is the closest possible to 8 min in order to have time 
to prepare the syringe, while the deformation of cement without incurring structural 
damage is still possible. Until now the majority of cements are prepared manually, placing 
the solid and liquid phase in a kind of mortar, and mixing it with a pestle and a spatula.33 
The mechanical behaviour of CPCs is also an important parameter, since in most of its 
clinical applications they are put in direct contact with the human cancellous bone, thus 
being expected that the mechanical strength required for the cement should be at least 
as strong as the trabecular bones. Unfortunately, CPCs are sufficiently strong only when 
submitted to compression. In practice, after setting, the mechanical strength of the 
cements is low when compared to that of bones, teeth or even calcium phosphate 
bioceramics. Thus, the products obtained after the hardening of all the CPCs are fragile, 
since they have a low impact resistance, while the resistance to compression ranges from 
10-100 MPa.  
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The poor mechanical properties reduce the clinical applicability of the CPC. There are 
some factors that can induce changes in the measured mechanical resistance, such as 
factors related to sample preparation and also in the measurement process.33 Some of 
these factors are summarized in Table 5. 
 
 
Table 5 – Factors that affect CPC (Adapted from Driessens FCM. et al 33). 
Factor Consequence 
S/L Ratio 
Higher ratio means higher solid phase resulting in higher 
resistance to compression. 
Ca/P ratio of the reagents 
Influence the nature of the, however the maximum 
compressive strength may vary depending on the formula. 
Particle size 
Smaller particles may lead to higher resistance to 
compression. 
 
Additives 
 
Can lead to increased or decreased mechanical strength 
depending on the type and amount used. 
Chemical stability 
The metastable products such as DCPD or OCP can be 
transformed under physiological conditions, becoming 
more stable and with low solubility such as CDHA, 
maintaining its strength indefinitely during storage in 
almost neutral aqueous solutions at 37 °C. 
Temperature 
Can lead to dehydration of the cement causing more 
porosity and consequently lower mechanical strength. 
 
 
The setting time of CPC is based on a dissolution reaction which occurs when powders are 
mixed with reactive liquid. However, their poor injectability, low strength and lack of 
macroporosity to bone growth have limited its use in clinical applications. The injectability 
of CPCs is extremely important in clinical applications involving defects with limited 
accessibility or narrow groove, when there is a need for a very precise placement of the 
paste to conform the bone defect area, or when using minimally invasive surgical 
techniques.29 
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2.2.3.2. Ready-to-use Injectable Bone Substitutes 
 
Given the limitations of CPCs, new (pre-mixed) injectable bioactive systems that could be 
used immediately were created. These bone substitutes are easier to use because they do 
not require any mixing or any transfer to an appropriate delivery system. Furthermore, 
there is no time restriction to use the product when it is open. The only disadvantage is 
linked to the predefinition of the mixture’s composition.23 
Since none of bone replacements proposed so far have load bearing, the principal 
strategy currently used to repair bone defects is to use a bone substitute that is rapidly 
resorbed and replaced by new mature bone. To achieve this, not only the chemical 
composition but also the geometry of the bone substitute must be optimized 18. The use 
of a bone substitute that can easily be crossed by blood vessels and cells is particularly 
important. For this purpose, it must have a completely interconnected porous structure 
with pore diameters and pore interconnections larger than about 50 µm.18 An approach 
to obtain a pasty bone substitute and macroporous is to combine granules with a 
hydrogel, e.g: dextran34 or sodium hyaluronate 35. Since the hydrogel solids content is 
generally very low, the cells can easily pass through the macroporous hydrogel gaps 
present between the granules. 
The size of the gaps is controlled by the percentage of hydrogel in the mix and by the size 
distribution of the granules.28 Thus, a bone substitute with superior biological properties 
is obtained. 
NovaBone Putty®, a calcium phosphosilicate and BG platform with additives, for 
application in bone regeneration is an example.36 The solid phase, bioactive, is composed 
by BG 45S5® particles and calcium phosphosilicates. The liquid phase comprises glycerol 
and polyethylene glycol (PEG). The bioactive phase allows the initial release of CaP and 
improves the physical characteristics of the paste, facilitating its handling. PEG occupies 
the spaces between the particles of the bioactive phase and also facilitates the handling 
of the putty, giving it a soft surface. Glycerol serves as a binder, has high hydrophilicity, 
and allows the consistency of the paste, retaining together all phases present.  
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The product overcomes the limitations of CPC and similar existing materials, is easy to 
handle, is conformable to the site of injury, is hydrophilic (mixes with blood), it has 
excellent retention at the injury site (remains locally) and a very smooth surface. All these 
properties result in rapid and complete resorption, osteoconduction and 
osteostimulation, leading to bone regeneration.36 
 
2.3. Legislation of Medical Devices 
 
Injectable bone substitutes are considered medical devices, as described in Directive 
93/42/EEC June 14th 1993 of the European Council and amended by M1 Directive 
98/79/EC, M2 Directive 2000/70/EC, M3 Directive 2001/104/EC, M4 Regulation (EC) 
1882/2003 and M5 Directive 2007/47/EC.37 According to it, a medical device is meant by 
"any instrument, apparatus, appliance, software, material or other article, whether used 
alone or in combination, including the software intended by its manufacturer to be used 
specifically for diagnostic and/or therapeutic purposes and necessary for the proper 
functioning of the medical device intended by the manufacturer to be used for human 
beings for the purpose of: 
- Diagnosis, prevention, monitoring, treatment or alleviation of disease, 
- Diagnosis, monitoring, treatment, alleviation or compensation for an injury or 
handicap,  
- Study, replacement or modification of the anatomy or of a physiological process,  
- Conception inspection, on which the main intended action in the human body is 
that it’s not achieved by pharmacological, immunological or metabolic means, but 
its function can be supported by such means; ".37 
According to the directive, to market a MD in the European Union is necessary to have 
the CE marking. To obtain the CE marking, there are certain requirements that need to be 
fulfilled, as schematised in Figure 5. Based on Figure 5 and Directive 93/42/EEC, there are 
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two ways to proceed to clinical evaluation of a MD and later obtain the CE marking. The 
first way is a critical evaluation of the scientific literature in order to obtain equivalence of 
the MD that is intended to release in the market, relatively to an already marketed MD 
which is reported in the literature. The other way is characterized by conducting an 
independent clinical trial that after drawing up a research plan, it is required an approval 
by the competent Ethics Committee. After the clinical evaluation, whether by equivalence 
or clinical trial, a design dossier must be developed and later submitted to the assessment 
of a notified body. In case of approval the CE mark is obtained. After approval by the 
notified body, it is necessary to notify the Competent Authority of the respective country 
(e.g: Portugal – INFARMED) of the intention to place the MD on the market, which 
complies with European accreditation. 
For the production of the MD, the entire procedure has to be done according to the a 
Quality Management System for example, according to EN ISO 13485:2003.38 
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Figure 5 – Representative scheme of the requirements to carry out a clinical evaluation and obtain 
the CE marking. 
 
 
Requirements of annex I of 
DL 145/2009
Request for conformity 
assessment
Clinical evaluation (annex XVI 
of DL 145/2009)
CE marking 
achievement
Two options
Clinical evaluation of 
Scientific Literature 
(safety, performance, conception 
characteristics and purpose of the 
device)
Demonstrated equivalence of the 
device under evaluation with the 
device placed in the market to which 
the data relates, considering clinical, 
technical and biological aspects
Final Report
(plan for the selection, data 
collection and analysis, definition of 
the objectives of the evaluation, 
identification of the collected data 
and respective publications; 
conclusions obtained)
Perform a Clinical 
Investigation
Elaboration of a Clinical 
Investigation Plan 
(ISO 14155 and Declaration of 
Helsinki)
Request for Opinion of the 
Competent Ethics 
Committee 
Declaration for Medical 
Devices under Clinical 
Investigation 
(Annex VIII)
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3. Preparation and Characterization of the Putty 
 
3.1. Experimental procedure 
3.1.1. β-TCP Synthesis  
 
β-TCP powder was obtained by chemical precipitation from calcium nitrate tetrahydrate 
[Ca(NO3).4H2O] (Panreac) and di-ammonium hydrogenphosphate [(NH4)2HPO4], (Panreac) 
as chemical precursors for calcium and phosphorus, respectively (Table 6).  
 
Table 6 – Precursors used in the synthesis of β-TCP powders. 
Reagent 
Chemical 
Formula 
Precursor 
Concentration 
(g/L) 
Di-ammonium 
hydrogenphosphate 
(NH4)2HPO4 P 79.236 
Calcium nitrate tetrahydrate Ca (NO3)2.4H2O Ca 211.163 
 
The calculations for the preparation of the solutions for use in the synthesis of β-TCP 
powder were based on a ratio Ca/P = 1.49. Assuming that the initial concentration of the 
P solution was fixed at 0.6 M, concentration of solution of the Ca precursor was 
calculated so that this ratio could be maintained. Therefore, the total concentration of 
the Ca precursor had to be 0.894 M. The di-ammonium hydrogenphosphate solution was 
slowly added via peristaltic pump with 88.6 mL/min flow rate to the calcium nitrate 
tetrahydrate solution previously placed in the reactor under stirring at a speed of 1000 
rpm. After complete admission of the solutions of precursors to the reactor, the pH of the 
solution/suspension mixture was controlled to 7 and maintained at this value by the 
initial addition of 70 mL of ammonium hydroxide (NH4OH; Sigma-Aldrich, Germany) 
solution. The pH value was measured and recorded, in an interval of 15 min, with a pH 
meter, within 3 h of synthesis, and maintained at pH 7 by adding ammonium hydroxide 
when necessary. The reaction was carried out at 30 °C under constant stirring speed of 
1000 rpm for 3 hours (h). The experimental details are summarised in Figure 6. 
44 
  
 
Figure 6 – β-TCP powders synthesis. 
 
The suspension of the precipitate was withdrawn from the reactor after 3 h of reaction. 
The precipitate was separated by filtration under vacuum and was then dried at 100 °C 
for 48 h. Then, it was deagglomerated and calcined at 1000 °C for 2 h, 5 °C min1. Finally, 
the powders were initially milled in a ball mill for 25 min and in an high speed agate mill 
for 20 min to obtain particles with mean particle size of 13 μm (determined by light 
scattering technique). The crystalline phases of the calcium phosphate powder were then 
investigated by X-ray diffraction (XRD) analysis. 
1. Weighing the reagents
2. Set the reactor with 30 °C temperature (Reaction must be carried out at 30 °C, 
under constant stirring speed of 1000 rpm for 3 hours)
3. Addition of the calcium nitrate tetrahydrate solution (2L) to the reactor
4. Addition of di-ammonium hydrogenphosphate solution (2L) via 
peristaltic pump to the calcium precursor (in the reactor)
5. Addition of 70 mL ammonium hydroxide solution
6. pH recorded every 15 minutes and maintained at pH 7 (addition of 
ammonium hydroxyde) within 3 hours synthesis
7. Filtration under vacuum of the precipitate
8. Drying at 100 °C for 48-72 hours
9. Deagglomeration
10. Calcination at 1000 °C, 2 hours, 5 °C/minute
11. Milling in ball mill (25 minutes) and high speed agate mill (20 minutes) 
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3.1.2. Bioglass Synthesis 
  
FastOsBG was prepared by the melt-quenching method, as diagrammed in figure 7. 
Homogeneous mixtures of batches (100 g), obtained by ball milling (5 minute mixture), 
were preheated at 900 °C for 1 h for decarbonization and melted in Pt crucibles at 1570 
°C for 1 h. The glass was obtained in frit form by quenching the glass melt in cold water. 
The frit was dried, ball milled for 15 min and milled again in a high speed agate mill for 
about 20 min, resulting in fine glass particles with mean particle size of 1015 μm. The 
amorphous nature of glasses was confirmed by XRD analysis. 
 
 
 
 
Figure 7 – Steps followed for the synthesis of FastOsBG. 
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3.1.3. Dehydration and milling of monocalcium phosphate monohydrate (MCPM) 
 
Monocalcium phosphate monohydrate, (Ca(H2PO4)2.H2O - MCPM, Sigma-Aldrich) was  
selected as the acidic component to react with β-TCP to promote setting after 
implantation when in contact with physiological fluid. Besides the stoichiometric water, it 
is also susceptible of attracting and holding water molecules from the surrounding 
environment at room temperature. The presence of water in the powder mixture (MCPM 
+ β-TCP + FastOsBG) is not desired as it would promote its early partial setting of the 
putty, therefore, compromising its shell life. Therefore, MCPM was previously dehydrated 
at 80 °C in a laboratory oven, followed by ball milling, drying and sieving as schematized 
in Figure 8. 
 
Figure 8 – MCPM treatment steps. 
 
The process had the duration of 3 days (d) and after that the MCPM powder with D50 
<100 µm was saved into a desiccator. A thermogravimetric (TG) analysis would give a 
more accurate description of the dehydration process of MCPM. Unfortunately the 
equipment was broken and the requested analysis is still pending. 
 
3.1.4. Putty preparation 
 
The calcium phosphate cement putty consisted of a solid phase (a mixture of FastOsBG, 
MCPM and β-TCP powders in the following volume ratios of 40:30:30) premixed in a 
liquid phase (Glycerol ≥ 99.5 %, Sigma-Aldrich). The planned solid/liquid (S/L) weight ratio 
was 3.3. Glycerol was firstly added to the container and then the powders were added 
according to their mean particle sizes, starting from the finest one (β-TCP) followed by 
FastOsBG, and finally MCPM. The mixture was stirred after each powder addition for 
25 min at 8001200 rpm in order to obtain a homogenous putty. Several syringes (1, 3 
and 5 mL) were then filled with the putty using a vacuum syringe charger.  
Drying
(1 day)
Ball milling
( ~ 5 min)
Drying
(1 day)
Ball milling
(~ 5 min.)
Drying
(1 day)
Sieving
47 
  
The overall putty preparation process is schematized in Figure 9. The syringe charger is 
not yet fully optimized for this kind of viscous pastes/putties and complete vacuum 
conditions could not be granted. 
 
Figure 9 – Putty preparation scheme. 
 
3.2. Characterization of starting powders 
 
The starting powders were characterized regarding crystalline phase composition and 
particle size distribution (PSD). The crystalline phases were analysed in a XRD 
diffractometer. The particle size distributions (PSDs) of β-TCP and FastOsBG powders 
were determined by light scattering technique using the Fraunhofer optical model. The 
PSD of MCPM powder cannot be assessed through a wet characterization technique using 
water as dispersing liquid due to its solubility in water. Therefore, the milled MCPM 
Obtaining final and 
homogenous putty
Ready-to-use 
injectable putty (final 
product) for 
characterization
Filling 1,3 and 5 ml 
syringes
Addition of : 
1. Glycerol 
2. β-TCP 
3. FastOS BG 
4. MCPM
Weighing of the solid 
and liquid 
components
Stirring of the 
mixture
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powder was passed through a 100 m mesh before being added to the putty formulation 
and characterized though Scanning Electron Microscopy (SEM).  
3.3. Putty Characterization 
   
The putty developed in this work is intended to be used clinically during surgery. To 
reduce the risk of errors the putty should be predictable, easy to use and it’s behaviour 
when applied in the body well known. 
 
3.3.1. Injectability 
 
To evaluate the injectability, only 5 mL syringes were used, as the syringes with lower 
capacities are smaller and won’t fit the wooden support of the injectability device 
available. Therefore, 5 mL syringes with putty were mounted in a universal testing 
machine, as shown in figure 10. A cross-head speed/force of 15 mm min1 was used to 
extrude the putty from the syringe. The extrusion rate was kept constant, while the force 
was recorded in the software. 
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Figure 10 – Injectability evaluation. 
 
The fraction of putty that could be extruded was determined by measuring the weight of 
the plastic syringe before and after extrusion. Therefore, the maximum fraction 
(injectability) could never reach 100 % since residual putty was always left. Injectability 
was calculated with the following formula: 
 
𝐼 =
𝑚 𝑖𝑛𝑗𝑒𝑐𝑡𝑒𝑑(𝑔)
𝑚 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 (𝑔)
∗ 100 %  (Equation 1). 
 
In this case, I is the injectability, minjected  and minitial  are the weight of the paste injected 
through the syringe and the paste initially contained in the syringe. All values were 
obtained from the average of three tests. 
 
 
 
50 
  
3.3.2. Phase and size separation 
 
In order to evaluate the phase and size separation of the putty, during injectability, in 
other words, to investigate the occurrence of filter pressing effect, putty samples were 
collected every 60 seconds counted from the beginning of the extrusion process. Samples 
were submitted to TG in order to investigate which thermal treatment was more suitable, 
since the liquid and organics need to be removed to investigate if S/L ratio remains the 
same before extrusion. After the TG result, the samples were weighed before and after 
calcination at 400 °C for 1 h using 2 °C min1 to determine their S/L values.  
 
3.3.3. Setting time 
 
To evaluate the setting time (ST) of the putty, it was injected into three cylindrical moulds 
(13 mm Ø; 10 mm height). At t = 0 the filled moulds were immersed in 10 ml of freshly 
prepared phosphate buffered saline solution (PBS, pH 7.4, approximately) at 37 °C, to 
stimulate in vivo conditions. The putty was considered to have set when the sample could 
support the weight of a 453.6 g Gilmore needle with a tip diameter of 1.06 mm without 
leaving a mark on the sample (FST)39.  
The three samples were tested consecutively every 5 min. However, the setting of the 
putty is very dependent on the diffusion of water into the putty replacing the glycerol. 
Therefore, the surface of the samples hardened before the bulk. Considering this, the 
time at which the tip of the needle didn’t leave any mark was when the bulk could 
support the weight without breaking. The putty was considered to have set when both 
sides supported weight of the needle. 
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Figure 11 – a) Method used to measure setting time in PBS at 37 °C; b) Application of the Gilmore 
needle in the putty (already set). 
 
 
3.3.4. Compressive Strength 
 
To measure the compressive strength (CS), the putty was injected into cylindrical moulds 
(13 mm Ø; 10 mm height) and immersed in 10 ml PBS at 37 °C in a sealed plastic cup. 
After 24 h, 7 and 28 d, the samples were removed from their moulds and smoothly 
polished to obtain the correct height and parallel surfaces. The maximum compressive 
strength until failure was measured using the same universal testing machine. The cross-
head speed was 11 mm min1 and a thin aluminium film was placed between the sample 
and the crosshead to reduce the effect of possible defects deriving from the putty surface 
or mould (Figure 12). At least three measurements were made for each sample. 
 
(a) (b) 
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Figure 12 – Compressive strength measurement of the putty (after failure). 
 
3.3.5. Bioactivity and Degradation in Simulated Body Fluid (SBF) and Phosphate 
Buffered Saline Solution (PBS) 
 
SBF, which has ion concentrations and a pH value similar to those of human blood 
plasma, was prepared in accordance with the Cuneyt Tas method. Initially, 960 mL of high 
purity deionized water was added to a 1000 mL capacity glass beaker, which was then 
placed in a hot plate/magnetic stirrer (solution must be stirred step by step). The Cuneyt 
TasSBF recipe was then prepared as follows: 
 
 
Figure 13 – Steps to obtain the Cuneyt Tas-SBF recipe. 
Addition of
6,5456 g NaCl
(stir
vigorously at
RT for 3 min)
Addition of
2,2682 g 
NaHCO3 
(stir vigorously
at RT for 3 
min)
Addition of
0,373 g KCl
(stir
vigorously at
RT for 3 min)
Addition of 
0.1419 g 
Na2HPO4
(stir
vigorously at
RT for 3 min + 
heat the 
solution to 37º 
C)
Addition of 
0.3049 g 
MgCl2.6H2O 
(stir vigorously 
for 3 min) 
Addition of 9 
mL of 1M HCl 
solution
(stir 
vigorously for 
3 min)
Addition of
0.3675 g 
CaCl2.2H2O
(stir
vigorously at
RT for 3 min)
Addition of
0.071 g 
Na2SO4
(stir
vigorously at
RT for 3 min]
Addition of
6.057 g Tris 
[=(CH2OH)3CN
H2]
(solution 
becomes 
turbid, keep 
stirring)
Addition of 30 
mL of 1 M HCl 
(keep stirring) 
until pH reach 
7.4 at 37 ºC
53 
  
27 mM HCO3-Tris SBF, with pH 7.4 at 37 °C is obtained. SBF solution was kept in a clean 
glass media bottle (1000 mL capacity), tightly capped, in a refrigerator. SBF solutions 
older than 30 d were never used. 
A litter of PBS, which is isotonic (osmolality and ion concentrations of the solution usually 
match those of the human body), was prepared as follows in a 1000 mL glass cup under 
constant stirring: 
 
Figure 14 – Steps to obtain PBS. 
 
PBS, with pH 7.4 at room temperature was obtained and stored in a plastic container, in a 
refrigerator. PBS solutions older than 7 d were never used.  
After setting for 24 h (1 d), the putty samples (13 mm Ø; 10 mm height) were immersed 
in 10 mL of both solutions at 37 °C for 7 and 28 d. For the evaluation of in vitro bioactivity, 
the samples were removed after incubation for the specified time periods, rinsed in 
deionized water and dried at room temperature until reaching a constant weight. The 
samples were characterized with XRD, and the surface morphologies were observed 
through SEM. 
Regarding in vitro degradation, the 24 h, 7 d and 28 d samples were immersed into PBS 
and SBF solutions at 37 °C. For this evaluation, the samples were removed after 
incubation for the specified time periods, rinsed in deionized water, dried at 80 °C for 24 
h and weighed. In vitro degradation was calculated through the following formula: 
𝐷 = [𝑊𝑜 − 𝑊𝑇)/𝑊𝑜] ∗ 100 % (Equation 2). 
 
In which, D is the degradation rate and W0 and WT are the dry weight of the initial sample 
and the degraded sample, respectively. These measurements were made in triplicate.  
Start with 
800 mL of 
distilled 
water:
Addition of 
8 g NaCl
Addition of
0.2 g KCl
Addition of
1.44 g 
Na2HPO4
Addition of
0.24 g 
KH2PO4
Adjust pH 
to 7.4 with 
the 
addition of 
HCl
Addition of 
distilled 
water to a 
total 
volume of 
1 liter
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3.3.6. Structural analysis 
 
The existence of crystalline phases in the developed putty was investigated through XRD. 
The infrared spectra of the putty was obtained using Fourier transform infrared 
spectroscopy (FTIR), in order to identify the functional groups present in the putty and 
support the results of XRD. The putty microstructure was analysed through SEM. The 
samples were placed in an aluminium holder with carbon glue. After drying in a 
laboratory oven during night, samples were coated with a carbon film using a carbon 
evaporator. 
 
 
3.3.7. Shelf life 
 
The shelf life is an important feature for putties and all implantable premixed cements. It 
tells about how long the putty can be stored while maintaining intact the relevant 
properties. Gbureck et. al.28 showed that dry powder mixtures of β-TCP and MCPM tend 
to react to form monetite in the presence atmospheric humidity. It was found that shelf 
life could be prolonged by storing the powder mixtures under dry (argon) atmosphere 
and low temperature, or by adding a retardant. In the present study, the syringes were 
filled with the putty, screw capped and stored in sealed plastic sleeves. Putty injectability, 
cohesion and hardening were checked week after week.  
 
 
3.4. Equipment, software and devices used 
 
This subchapter is intended to report on the equipment, software and devices used in the 
production and characterization of raw materials and putties. These are presented in 
Table 7. 
 
55 
  
Table 7 – Equipment, software and devices used in the production and characterization of raw 
materials and putty. 
Type of equipment Brand and model name 
Production of starting materials of putty 
Ovens used in the calcination of β-TCP 
powders and fusion of FastOsBG 
Termolab 
pH meter Consort C1010 
Ball mill Ceramic Instruments, Sassuolo - Italy 
High speed agate mill Retsch PM14 
Laboratory ovens MMM Medcenter ECOCELL 
Mixer THINKY ARE-250 
Vacuum syringe charger THINKY ARC-40H 
Syringes SOFT-JECT Luer Lock 
Characterization 
Setting time Controls 63-L0075 
XRD 
Rigaku Geigerflex D/Max, Tokyo, Japan; C 
Series; (CuKa radiation; 2h angle range 10–
80°; step 0.02°s1) 
Particle Analyser Coulter LS 230 
Injectability and compressive strenght 
Universal testing machine: SHIMADZU AG-IS ; 
software: TRAPEZIUM 2 
SEM 
HITACHI S-4100 (constituted of an electron 
emission system with tungsten filament, 
acceleration 10 kV and 15 Å maximum 
resolution) 
Carbon evaporator EMITECH 
FTIR 
Mattson Galaxy S-7000, USA (powders were 
mixed with KBr in the proportion of 1.5/200 
(by weight) and pressed into a pellet using a 
hand press). In total, 128 scans for 
background and 64 scans per sample were 
made with a signal gain of 1. The resolution 
was 4 cm-1. 
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3.5. Legislation of Medical Devices 
 
The clinical evaluation of the MD is a key step to pave the way towards its commercial 
release. To proceed to the clinical evaluation of the MD, a critical evaluation of the 
scientific literature was made, in order to obtain equivalence of the MD relatively to an 
already marketed MD, reported in the literature.  
Therefore, in order to meet the essential requirements set out in Annex I of the Directive 
93/42/EEC, a clinical evaluation report (CER) has been carried out. Its structure is 
supported on the document MEDDEV. 2.7.1 Rev.3.40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
  
 
 
 
 
 
 
CHAPTER IV 
 
RESULTS AND DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
58 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
  
5. Results and Discussion 
 
5.1. Powder Characterization  
 
5.1.1. β-TCP 
 
The XRD pattern of the precipitated calcium phosphate powder after being heat treated 
at 1000 °C with a heating rate of 5 °C/min is displayed in Figure 15. The diffractogram was 
analysed using PDF files (Powder Diffraction Files) of ICDD (International Centre for 
Diffraction Data) and the standard diffraction lines for β-TCP (PDF file 04-006-9376) and 
for Calcium Pyrophosphate (CPP) (PDF file 04-009-3876) are also plotted in Figure 15 for 
comparison. Figure 15 also shows the results of crystalline phase analysis determined by 
using the Reference Intensity Ratio (RIR), revealing that the β-TCP powder consists of 81% 
β-TCP and 19% CPP phases. This significant amount of CPP phase is likely due to an 
insufficient alkalinity of the media during precipitation. 
 
 
Figure 15 – X-Ray Diffractogram of β-TCP powder. (CPP: Calcium Pyrophosphate, Ca2 (P2O7), ICDD 
04-009-3876; β-TCP: Beta-Tricalcium Phosphate Ca3 (PO4)2, ICDD 04-006-9376). 
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The calcined β-TCP powder was dry milled in order to obtain an adequate particle size 
distribution. The particle size distribution curve of the β–TCP powder is presented in 
Figure 16. The particle diameters (D10, D25, D50; D75, and D90) below which typical volume 
percent values (10%, 25%, 50% 75% and 90%) of the distribution lie below are reported in 
Table 8. The D50, the median, is defined as the diameter where half of the population lies 
below this value. It can be seen that the β–TCP powder has a bimodal particle size 
distribution, with median particle size (D50) of 1.5 µm. The coarser particle population 
centred at about 89 µm in Figure 16 is likely due to the presence of some agglomerates 
that were not completely destroyed upon milling.   
 
 
Figure 16 – Particle size distribution of β–TCP powder. 
 
 
Table 8 – Particle size distribution intervals of β–TCP powders. 
Volume [%] < 10 < 25 < 50 < 75 < 90 Mean 
Particle Diameter [µm] 0.263 0.632 1.509 3.270 6.963 2.491 
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5.1.2. FastOsBG 
 
The XRD pattern of FastOsBG powder is presented in Figure 17. The absence of 
crystalline phases is obvious, which confirms the amorphous nature of the BG.  
 
Figure 17 – X-Ray Diffractogram of FastOsBG frit. 
 
FastOsBG was then submitted to milling, to obtain the required particle size distribution. 
The particle size distribution curve of the FastOsBG frit dry milled for 35 min is 
presented in Figure 18. Like for the β–TCP powder, the particle diameters (D10, D25, D50; 
D75, and D90) for the FastOsBG frit are also reported in Table 9. The results indicate a 
relatively broad particle size distribution with D50 14 µm. According to Aberg30, the 
injectability of the putties is enhanced when a broad particle size distribution of the 
materials is used. 
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Figure 18 – Particle size distribution of FastOsBG. 
 
 
Table 9 – Particle size distribution intervals of FastOsBG. 
Volume [%] < 10 < 25 < 50 < 75 < 90 Mean 
Particle Diameter [µm] 1.203 4.213 13.72 27.73 42.57 17.92 
 
 
5.1.3. Monocalcium Phosphate Monohydrate (MCPM) 
 
MCPM is a highly soluble and hygroscopic compound. Therefore, the assessment of its 
particle size was made by SEM observations. Figure 19 shows the size/morphology of the 
MCPM particles as received (a) and after the dehydration and milling processes (b). It can 
be seen (Figure 19 (a)) that the as received powder consists of well faceted and 
rhombohedral particles, some of them with several hundreds of microns in size. After 
milling, the MCPM particles show clear evidenced of comminution (smaller and isometric 
particles, as seen in Figure 19 (b)). The sizes observed in Figure 19 (b) are in fair 
agreement with the expected ones for a powder passed through a 100 µm mesh.  
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Figure 19  – (a) SEM image of as received MCPM powders; (b) SEM image of dehydrated and 
milled MCPM powders (before mixing). 
 
 
 
5.2. Putty Characterization  
 
5.2.1. Injectability 
 
The predefined volume ratios of the powders used in the putty formulation were 
FastOsBG : β-TCP : MCPM = 40:30:30 and the total S/L volume ratio was 60/40. 
Considering the density of each powder and of the Glycerol, the resulting S/L weight ratio 
is 3.3. These conditions ensured good injectability results as shown in Table 10. The three 
syringe samples showed that the putty was easily expelled and kept cohesion. The 
percentages of Injectability (%I) were always > 95%, with a mean of 96%. These values 
are excellent considering the relatively high S/L ratio used.  
 
 
 
 
 
(a) (b) 
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Table 10 – Injectability percentage Results. SN – Syringe Number; SaN - Sample Number; S – 
Syringe weight (g); S + P – Syringe + Putty weight (g); S + LO – Syringe + Leftover’s weight (g); S + 
LO – Syringe + Leftover’s weight (g); GC – Glass Container weight (g); GC + P – Glass Container + 
Putty weight (g); EP – Extruded Putty weight (g); TEP – Total Extruded Putty weight (g); P – Putty 
weight (g); % I - % Injectability; Mean – Mean % Injectability 
SN SaN S (g) S+P (g) S+LO (g) GC (g) GC+P (g) EP (g) TEP (g) P % I Mean (%) 
1 
1 
5.29 
15.8 5.69 
47.1 49.57 2.47 
10.13 10.51 96.38 
96.38 
2 47.87 52.01 4.14 
3 29.53 33.05 3.52 
2 
4 
15.64 5.7 
47.37 49.97 2.60 
9.91 10.35 95.75 5 29.65 33.50 3.85 
6 47.86 51.32 3.46 
3 
7 
16.01 5.60 
44.62 47.92 3.30 
10.41 10.72 97.11 8 50.39 53.85 3.46 
9 43.72 47.37 3.65 
 
 
 The injectability curves are displayed in Figure 20. They include a first initial increase of 
the extrusion force up to a kind of roughly constant plateau, and end by a steep increase 
of the extrusion force when almost all the putty has been expelled.  
 
Figure 20 – Injectability curves for SN 1, 2 and 3.  
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The first initial increase is related to the yield stress of the putty and the gradual breaking 
down of its internal structure. The plateau means the force required for keeping a 
constant flow. And finally, the last steep increase is solely due to the exhaustion of the 
putty in the syringe. 
The injectability profiles also show small irregularities, which are attributed to some 
deficiencies of the syringe filing process. Namely, the vacuum could not be completely 
granted due to the relatively high viscosity of the putties and some air bubbles became 
entrapped inside. This explains the shape of the injectability curve 2 (SN 2) in which 96% 
of the putty was extruded under an applied maximum force of 80 N. Therefore, the 
injectability curves 1 and 3 (SN 1 and 3, Figure 20) seem to be the most representative of 
the extrusion behaviour of the putties. The easiness of the extrusion process suggests 
that filter pressing effect is likely to be absent.  
 
 
5.2.2. Phase and size separation 
 
The injectability performance is evaluated based not only on the percentage of extruded 
paste but also in terms of its homogeneity along the entire process. Therefore, it is 
essential analysing the eventual occurrence of solid/liquid phase segregation during 
injection.41 If the firstly extruded putty sample contains a higher proportion of liquid than 
exists in the initial mixture, this is an indication that the FPE has occurred. In order to 
investigate this, three putty samples from each syringe were collected at different time 
points along the extrusion, submitted to thermal treatment at 400 °C and the S/L ratio 
was determined.  
Regarding TG results (Figure 21), the total weight loss of the putty was 14% up to 400 °C, 
followed by a constant plateau with further increasing the temperature up to 500 °C. 
Therefore, all the collected putty samples were heat treated at 400 °C to determine the 
S/L ratios. The data reported in Table 11 show that the experimental weight S/L ratio 
values determined after the heat treatment at 400 °C ranged from 2.76 to 2.94.  
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These values differ from the theoretically planned S/L weight ratio value of 3.3, assuming 
that the MCPM was a solid. However, as its name indicates, this compound contains one 
mole of water per mole of MCPM, which is lost upon heat treating at 400 °C. Moreover, 
MCPM is a hygroscopic compound and is likely to further hydrate in contact with the 
atmosphere. This explains why the differences between the planned and the 
experimental S/L ratio values are higher than expected. 
Figure 22 shows the evolution of the S/L over the measurement numbers for each 
syringe. The results show that the calculated S/L in each measurement number (MN) for 
each syringe are very similar (and almost the same when rounded to one decimal place) 
and the S/L in the first MN for each syringe is always higher than the following MN. 
Having this in mind and observing the S/L curves for each syringe the filter pressing effect 
is clearly absent. 
 
Table 11 – Phase and size separation results. SN - Syringe Number; MN – Measurement Number; 
GC+EP – Glass Container + Extruded Putty weight (g); GC+CP – Glass Container + Calcined Putty 
weight (g); ΔP – Liquid Phase weight (g); EP – Extruded Putty weight (g); S – Solid Phase weight 
(g); S/L – Solid to Liquid Ratio; Mean – S/L mean; SD – Standard Deviation; MM – Mean of mean; 
S/L (T) – Theoretical S/L 
SN MN GC+EP (g) GC+CP (g) ΔP (g) EP (g) S (g) S/L Mean SD 
MM 
1 
1 49.57 48.93 0.64 2.47 1.83 2.86 
2.85 0.02 
2.86 
2 52.01 50.94 1.07 4.14 3.07 2.87 
3 33.05 32.13 0.92 3.52 2.6 2.83 
2 
1 49.97 49.31 0.66 2.6 1.94 2.94 
2.91 0.03 2 33.5 32.51 0.99 3.85 2.86 2.89 
3 51.32 50.43 0.89 3.46 2.57 2.89 
3 
1 47.92 47.07 0.85 3.3 2.45 2.88 
2.83 0.06 2 53.85 52.95 0.9 3.46 2.56 2.84 
3 47.37 46.4 0.97 3.65 2.68 2.76 
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Figure 21 – TG results of the putty when calcined at 500 °C for 1 h with a heating rate of 2 °C/min. 
 
 
 
 
Figure 22 – S/L evolution over the measurement numbers (MN) for each syringe. Theoretical 
value is indicated by the red dashed line for comparison purposes. 
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5.2.3. Setting time 
 
Regarding this premixed cement/putty, it is not only the chemistry determining the 
setting time but also the water-glycerol exchange rate, the dissolution rate of MCPM 
particles and the strength of the putty after hardening are important factors.24 These will 
determine how fast the putty obtains sufficient strength to bear the load of the Gilmore 
test needle. The setting time results of the putty, when immersed in PBS (pH 7.4) at 37 °C 
are presented in Figure 23. 
In this specific case S/L weight ratio was kept constant (3.3), since the putty formulation 
was predefined. Measuring the ST of this putty can be tricky since the surfaces of the 
putty sample set first than the bulk. This is determined by the diffusion rate of water 
molecules into the bulk of the putty sample.   
ST results ranged from 24 to 27 min with a mean of 25.33 min, which are reasonable. 
However, a target ST would be below 20 min might require the addition of acidic 
components to the mixture that act as hardening accelerators.30 Decreasing the particle 
sizes of the reacting solid components (β-TCP, MCPM) is another alternative approach 
towards shortening the ST, as reported elsewhere.30 The resulting higher specific surface 
areas make reactions to go faster. 
 
Figure 23 – Setting time results of the putty when immersed in PBS (pH 7.4) at 37 °C. 
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5.2.4. Mechanical Properties 
 
The parameters used to control the mechanical properties of CPC that are also valid for 
putties are S/L ratio and particle size. Higher S/L gives stronger cement (less liquid in the 
putty composition) since the porosity is reduced. Controlling the mechanical properties 
with particle size is more complicated since it will need optimization of the size 
distribution of all powders used in the formulation.30 
Figure 24 shows the compressive strength results of the putty after immersion in PBS for 
1, 7 and 28 d. It is clear that the CS increases with prolonged time during immersion, 
especially from 1 to 7 d. The difference between 7 and 28 d is minimal or non-existent, 
therefore it is possible to conclude that the putty reaches its maximum compressive 
strength on the 7th day. 
 
 
 
Figure 24 – Compressive strength results of the putty after immersion in PBS for different time 
periods. 
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5.2.5. Bioactivity and Degradation 
 
The samples were prepared by injecting the putty into several moulds with the same size 
and format as used before. The filled moulds were immersed for 1, 7 and 28 d in PBS and 
SBF solutions. The degradation rates were characterized by the weight losses undergone 
by the samples along the immersion periods. The results are presented in Figures 25 and 
in Tables 12, 13, 11 and 14. Figure 25 shows that degradation rate in PBS steadily 
increases with increasing immersion time, oppositely to what happened upon immersing 
the samples in SBF where an overall decreasing trend was observed.  
The lower degradation rate in SBF is not surprising considering that this solution is close 
to saturation. Moreover, with the gradual dissolution of solid particles the solution is 
likely to reach a supersaturation degree. Under these conditions an apatite layer tends to 
precipitate at the surface of the solid components.4 The deposited surface layer is 
expected to exert a gradual hindrance towards further dissolution of solid components. 
This helps explaining the divergence observed in the degradation profiles in PBS and SBF 
(Figure 25). However, the weight variations in SBF show high deviation values between 
immersion time intervals, making it difficult to draw firmer conclusions.  
Despite the slower degradation rates in SBF, the samples immersed in SBF were much 
more damaged than the putty samples immersed in PBS. 
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Figure 25 – Evolution of weight loss of the putty samples upon immersion in PBS and in SBF 
solution solutions for various periods. 
 
 
 
 
Table 12 – Degradation rates after 24 h of putty immersion in PBS and SBF solutions (starting pH = 
7.4). T (d) – Time of incubation in days; N – Sample Number; M – Mould weight (g); M + S – Mould 
+ Sample weight (g); W0 – Dry weight of initial sample; WT – Dry weight after degradation; D – 
Weight loss (%); Mean (D) – Mean weight loss (%) 
Medium 
T 
(d) 
N 
M 
(g) 
M + S 
(g) 
pH 
W0 
(g) 
WT 
(g) 
D 
(%) 
Mean (D) 
PBS 1 2-1P 0.96 3.16 7.37 2.20 1.86 15.45 
17.21 PBS 1 2-2P 0.97 3.12 7.33 2.15 1.80 16.28 
PBS 1 2-3P 0.87 2.88 7.29 2.01 1.61 19.90 
SBF 1 2-1S 0.90 2.91 7.50 2.01 1.69 15.92 
16.48 SBF 1 2-2S 0.84 2.74 7.54 
1.90 1.59 16.32 
SBF 1 2-3S 0.95 3.16 7.37 2.21 1.83 17.19 
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Table 13 – Degradation rates after 7 days of putty immersion in PBS and SBF solutions. T (h) – 
Time of incubation in hours; T (d) – Time of incubation in days; N – Sample Number; M – Mould 
weight (g); M + S – Mould + Sample weight (g); W0 – Dry weight of initial sample; WT – Dry weight 
after degradation; D – Weight loss (%); Mean (D) – Mean weight loss (%) 
 
Medium 
T 
(d) 
N 
M 
(g) 
M + S 
(g) 
pH 
W0 
(g) 
WT 
(g) 
D 
(%) 
Mean (D) 
PBS 7 2-1P 0.84 2.83 7.45 1.99 1.56 21.61 
21.03 
PBS 7 2-2P 0.87 2.75 7.41 1.88 1.48 21.28 
PBS 7 2-3P 0.88 2.71 7.28 1.83 1.46 20.22 
SBF 7 2-1S 0.9 2.78 7.50 1.88 1.69 10.11 
 
13.25 
SBF 7 2-2S 0.84 2.74 7.54 1.90 1.59 16.32 
SBF 7 2-3S 0.95 3.16 7.37 2.21 1.83 17.19 
 
 
 
Table 14 – Degradation rates after 28 days of putty immersion in PBS and SBF solutions. T (h) – 
Time of incubation in hours; T (d) – Time of incubation in days; N – Sample Number; M – Mould 
weight (g); M + S – Mould + Sample weight (g); W0 – Dry weight of initial sample; WT – Dry weight 
after degradation; D – Weight loss (%); Mean (D) – Mean weight loss (%) 
 
Medium T (d) N M (g) M+S (s) pH W0 (g) WT (g) D (%) Mean (D) 
PBS 28 2-1P 0.98 3.27 7.32 2.29 1.83 20.09 
20.36 PBS 28 2-2P 0.90 2.90 7.37 2.00 1.58 21 
PBS 28 2-3P 0.95 2.95 7.41 2.00 1.60 20 
SBF 28 2-1S 0.88 2.81 7.57 1.93 1.52 21.24 
21.06 SBF 28 2-2S 0.90 2.87 7.53 1.97 1.56 20.81 
SBF 28 2-3S 0.90 2.84 7.53 1.94 1.53 21.13 
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5.2.6. Structural Analysis 
 
The hardened cements were characterized by different techniques (XRD, FTIR and SEM) 
to assess their microstructural and morphological features. The smaller fragments of the 
samples used in the CS tests were submitted to XRD analysis.  
The XRD diffractogram of the specimens immersed in PBS for 1, 7 and 28 d are shown in 
Figure 26. It can be seen that the phase crystalline assemblage gradually changed along 
the immersion time. β-TCP is the main phase in all the tested samples, but monetite 
phase was also identified after 1, 7 and 28 d of immersion in PBS.  
 
 
Figure 26 – XRD of the putty after immersion in PBS for different time periods. 
 
As mentioned by Aberg30, there are plenty of experimental evidences reported in 
literature that monetite is formed when β-TCP and MCPM are prepared as a premixed 
non-aqueous CPC. This is likely due to the shortage of water molecules upon starting 
hydration reactions. The monetite formation is also favoured at higher temperatures, 
being therefore fostered at the body temperature in comparison to the room 
temperature.30 Therefore, only monetite was detected as a new formed during the 
different immersion times, together with the some unreacted β-TCP.  
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MCPM and FastOsBG were not expected to be identified by XRD, the first for being 
highly soluble, and the second one for being amorphous. As seen from the diffractogram, 
no apatite could be identified in the incubated samples. This might be caused by the 
presence of calcium pyrophosphate, which has been shown to inhibit apatite crystal 
formation42. To dispel the doubts and to be sure about the formed crystalline phases, the 
putty samples were also submitted to FTIR analysis. 
 
FTIR spectra of the same samples used for the XRD analysis are presented in Figure 27. 
From a general point of view, the spectra of all samples are similar, varying only in the 
number of identified peaks and transmittance [%], the latter increasing with higher 
immersion time in PBS. Curiously, the sample immersed for 1 day has more identified 
peaks than the others. Only the main peaks found in all samples are presented. The peaks 
and the associated functional groups are identified according to the literature.43–49  
The monetite bands detected and their corresponding assignments are shown in Table 
15.  
 
Figure 27 – FTIR spectra of the putty after immersion in PBS for different time periods. 
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Table 15 – IR monetite wavenumbers and its corresponding assignments (Adapted from Salimi 
et.al.45). 
Monetite Wavenumbers [cm1] Assignments 
3461 OH stretching of residual free water 
2921 CH stretching 
2852 CH stretching 
1637 HOH bending and rotation of residual free water 
1419 Carbonate (from atmosphere) 
1400 POH in plane (bending) 
1130 PO stretching 
1064 PO stretching 
902 PO(H) stretching 
583 OPO(H) bending mode 
530 OPO(H) bending mode 
 
Considering the information available in the literature (Table 15), the bands around 
587.86, 1066.55, 1643.83 and 3418.42 cm1 can be associated with monetite.45 Therefore 
the FTIR spectra of the putty samples also confirm that monetite has been formed during 
the immersion period. Due to small available amounts of water within the putty during 
immersion, the MCPM concentration becomes high, causing lower pH, which leads to 
more monetite formation. Monetite cements have shown the potential to be 
osteoconductive, with the amount of bone formation being highly dependent on the site 
of implantation and the vascular supply, as an adequate blood supply can quicken cement 
resorption and replacement by new woven bone.50 
The band at around 462.17 cm–1 can be attributed to Si–O–Si bending modes of BG, while 
the band at around 726.07 cm–1 may be due to Si–O–Si symmetric stretching with 
simultaneous Si cation motions. Further, the band centred at around 553.06 cm–1 
corresponds to P–O bending modes. In addition to that, the band appearing at 1066.55 
cm–1, can also be assigned to Si–O–Si stretching vibrations. These bands indicate the 
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development of interfacial high-area silica gel layer, as postulated in Hench’s inorganic 
reactions set.46–49 
The peaks at around 553.06, 587.86 and 1066.55 cm–1 are present in all samples and are 
evidences of the formation of hydroxyapatite and other crystalline phosphate species, as 
these bands correspond to P–O bending vibrations in a PO4–3 tetrahedron.43,44,48  
Putty samples after immersion in water, and in PBS were observed by SEM. Figure 28 
presents the SEM images of putty samples immersed in water and PBS for 1 d and 28 d.  
 
 
Figure 28 – (a) SEM images of the putty after 1 d immersion in distilled water; (b) 1d in PBS and (c) 
28 d in PBS. 
 
 
 
(a)
(b)
(c)
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The aim was to investigate the interaction differences between the putty and the 
immersion media. FastOsBG, β-TCP, and MCPM particles could be easily identified in 
Figure 28. Figure 28 (a) shows the microstructure of the putty after 1 d of immersion in 
water. In the presence of water the putty sets quickly, due to the presence of MCPM (it 
quickly dissolves in water). The fluid exchange between putty and water is also faster 
under these conditions, which led to the formation of an apatite layer well visible on the 
surface of the hardened cement sample. 
Figure 28 (b and c) show the microstructure of the putty samples after 1 d and 28 d of 
immersion in PBS, respectively. Since PBS has higher ionic concentration, the fluid 
exchange is slower and therefore the presence of the apatite layer is not so clear. 
However there is a noticeable evolution of the putty microstructures from 1 d to 28 d, 
with the latter showing better developed crystals and larger pore sizes.  
 
5.2.7. Shelf life 
 
After 6 weeks of storage at room temperature the putty could not be injected, since it 
had undergone partial hardening of drying. This might be due to the insufficient 
dehydration of MCPM. The stoichiometric water carried by MCPM and water vapor from 
the atmosphere during the preparation process is likely to undertake partial setting 
reactions. When the putty is stored in prefilled sealed syringes the total amount of water 
present in the cement will be determinant for the shelf life. It was also found that shelf 
life can be improved by lowering the temperature. Therefore the syringe filling method 
and the storage conditions are important for the shelf life. Shelf life needs to be further 
investigated in order to extend it enough to allow an industrial design. Similar findings 
have been reported by Gbureck.28 
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5.3. Legislation of Medical Devices  
 
In accordance with Rule 8 of Annex IX to Directive 93/42/EEC:  
“All implantable devices and long-term surgically invasive devices are in Class IIb unless 
they are intended: 
— To be placed in the teeth, in which case they are in Class IIa, 
— To be used in direct contact with the heart, the central circulatory system or the 
central nervous system, in which case they are in Class III, 
— To have a biological effect or to be wholly or mainly absorbed, in which case 
they are in Class III, 
— Or to undergo chemical change in the body, except if the devices are placed in 
the teeth, or to administer medicines, in which case they are in Class III.’ 
Considering this, the developed putty is considered a class III MD. In order to meet the 
essential requirements set out in Annex I of the Directive 93/42/EEC, the clinical 
evaluation carried out has given rise to the documents annexed in this thesis:  Clinical 
evaluation report (CER) 03_01, Instructions for Use (IFU) 03_01, Datasheet (DS) 03_01 
and Product Description (PD) 03_01.  
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6. Conclusion and prospects 
 
6.1. Conclusion 
 
Putties constitute a recent innovation in the market of medical devices. The results 
obtained in this work are encouraging and support the conclusion that the handling is 
where the ready-to-use injectable bone substitutes have their biggest advantages. A wide 
use of putties in the clinics would shorten operation times and reduce infection rates to 
the benefit of both patients and medical staff and at the same time, it would cut the costs 
for these procedures.  
The obtained putty has a set of interesting features, including a relatively high solid/liquid 
weight ratio of 3.3, mean ST of 25.33 min, 96% of injectability coupled with the absence 
of FPE, and a maximum CS of 6 MPa, which is closer to normal mixed cements with the 
same composition and similar to that of trabecular bone. Therefore, the putty has an 
excellent handling ability and the strength after hardening competes with that of normal 
mixed cements. The structural analyses (XRD and FTIR) of the putty after immersion in 
PBS and water show the formation of monetite in the hardened cements and apatitic 
layer at the solid/liquid interface (SEM). These findings are indicators that the putty has 
the potential to be osteoconductive, being approppriate for bone regeneration. 
There are still a few shortcomings related to the following key aspects: setting time and 
shelf life. Both are interrelated and there are ways to enhance these properties, either by 
using MCPA instead of MCPM and/or by the storage at lower temperatures. The syringe 
filling method (under vacuum conditions) also needs to be improved to grant an efficient 
degassing of the putty. The setting time should desirably be shortened from the current 
25 min to 15-20 min without deteriorating the shelf life (6 weeks).  
The clinical evaluation report, CER_03_01, and other documents, DS_03_01, IFU_03_01 
and PD_03_01 are settled. The product name of the developed putty is BonActivePutty. 
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6.2. Prospects 
 
In order to cope with the above referred shortcomings, the future work prospects should 
address the effects of adding acidic compounds or other type of additives to decrease the 
ST of the putty without shortening its shelf life and the use of MCPA instead of MCPM, in 
order to verify if the shelf life increases are also planned.  
The putty was characterized regarding its performance only in simulated body fluids. 
Having that in mind, in vitro cell culture and in vivo studies are the next key steps to push 
this project forward.  
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1. General details 
Device name: BonActive®Putty 
Device manufacturer: Reg4life – Regeneration Technology, S.A. 
2. Description of the device and its intended application 
 
BonActive®Putty is a synthetic, bioactive and osteoconductive bone graft substitute. It is supplied 
sterile and is ready-to-use. This medical device consists of a mixture between a solid phase 
(FastOS®BG, β-TCP and MCPM) and a liquid phase (Glycerol). It is composed solely of elements 
that exist naturally in normal bone (Ca, P, Na, Si, O).  
 
This medical device can be clinically applied for the regeneration of hard tissues. The device is 
injectable, fast absorbed and replaced by new bone tissue during the healing process. 
BonActive®Putty is indicated to be injected into bone voids or gaps to fill and/or augment 
orthopaedics, oral, dental intraosseous and cranio-maxillofacial defects.   
 
BonActive®Putty is sterilized by gamma irradiation and is available in syringes, in different unit 
sizes. 
 
For more information please see Product Description (PD 03_01), Datasheet (DS 03_01) and 
Instructions for Use (IFU 03_01).  
4. Intended therapeutic indications and claims 
 
BonActive®Putty is indicated for use as an osseous defect filler for bone regeneration in dentistry, 
cranio-maxillofacial surgery and orthopaedics. Thus, BonActive®Putty indications for use are: 
  
Dentistry 
• Correction of periodontal and furcation defects. 
• Socket regeneration – ridge preservation. 
• Graft material for bone regeneration to be used during oral implant surgery. 
 
Cranio-maxillofacial surgery 
5. • Bone cavity filling in cranio-maxillofacial area including the jaw. 
• Frontal or maxillary sinus obliteration. 
 
 
Orthopaedics 
• Bone cavity filling. 
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• Bone cavity filling in the extremities and pelvis. 
• Bone cavity filling in the treatment of bone tumours.  
 
Instruction For Use (IFU 03_01) describe the correct use and application.  
 
4. Context of the evaluation and choice of clinical data types 
 
In the last years, a large number of commercial ceramic based cements and putties have been 
introduced as bone graft substitutes2. Putties, also called premixed/ready-to-use cements or non-
setting pastes, are a particularly strong and recent trend. Its production is less tricky than of 
cements and their biological response is often better2. These bone substitutes are also easier to 
use because they do not require any mixing or any transfer to an appropriate delivery system. 
Therefore, the handling of these bone substitutes is its biggest advantage2. 
A wide use of putties in the clinical practice would shorten operation times and reduce infection 
rates to the benefit of both patients and medical staff and at the same time, it would cut the costs 
for these procedures3. 
BonActive®Putty is a bone graft substitute with several applications and consists of a mixture 
between a solid phase (FastOS®BG, β-TCP and MCPM) and a liquid phase (Glycerol). 
 
It can be delivered to the operating room in a prefilled, sealed and ready-to-use syringe. When 
injected, the putty will be exposed to the body fluid present in the bone, where the non-aqueous 
liquid (glycerol), which is easily soluble in water, diffuses out from the cement while body fuild 
(mainly composed by water) diffuses into the cement causing it to set 3. 
 
Table 1 describes the compositions (in vol. %) of BonActive®Putty and its commercial equivalent 
medical device, NovaBone Putty ®.  
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Table 1 – Solid and liquid phases composition and the S/L ratio in BonActive®Putty and in its commercial 
equivalent medical device Novabone Putty®. 
 Solid Phase  Liquid Phase  S/L 
ratio 
(vol. %) 
45S5 
Bioglass® 
FastOs®BG β-TCP MCPM Gly PEG 
Novabone® 
Putty 
100 % 0 % 0 % 0 % 60 % 40 % 70/30 
BonActive® 
Putty 
0 % 40 % 30 % 30 % 100 % 0 % 60/40 
 
According to Table 1, BonActive®Putty is equivalent to the commercialized putty. The changes in 
composition are related to: 
- Components, namely : 
o Different bioactive glass; 
o Absence of PEG in the liquid phase; 
o Higher Glycerol concentration; 
o β-TCP addition; 
o MCPM addition; 
o Different S/L ratio. 
Differences in composition of the bioactive glasses are displayed in Table 2. 
Table 2 – Comparison between FastOs®BG and 45S5 Bioglass® (in mol %). 
 
 
 
 
 
Considering Table 2, FastOs®BG has some compositional differences when compared with 45S5 
Bioglass®. These changes are related to: MgO and CaF2 addition, raise in CaO and P2O5 
concentration, reduction in SiO2 and absence of Na2O. All these changes were introduced to 
overcome some shortcomings of 45S5 Bioglass®. For example, high amounts of Na2O make the 
glass surface highly reactive in physiological environments, leading to fast degradation rates not 
matching the new bone ingrowth, loosening of the bonding strength to living tissues and some 
cytotoxicity effects4–7.  
The incorporation MgO and CaF2 of in the constitution of bioactive glasses is based on a biological 
and medical explanation. Regarding magnesium (Mg) this is one of the most important mineral 
elements in the bone matrix, and more than half of the total physiological magnesium are stored 
in bone tissues8. A relevant role of Mg in the development of bone tissue is related to adhesion 
and growth of osteoblasts8. Therefore Mg have a key role in bone tissue development, and the 
Bioactive glass SiO2 P2O5 CaO Na2O MgO CaF2 
45S5 Bioglass 46.10 2.60 26.90 24.40 0.00 0.00 
FastOsBG 38.49 5.61 36.07 0.00 19.24 0.59 
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ability of MgO to modify the physical, thermal, and mechanical properties of silicate systems, 
stimulated the incorporation of Mg in the bioactive glasses compositions8.Regarding fluoride, in 
dentistry it is well known that this component prevent dental cavities by inhibiting enamel and 
dentine demineralisation, enhancement of remineralisation and inhibition of bacterial enzymes9. 
Furthermore, an important factor in this context is the formation of fluorapatite in physiological 
solutions, as fluorapatite is more acid resistant than carbonated hydroxyapatite, the main 
component of enamel and dentine. In orthopaedics fluoride is also known to increase bone 
density and despite a narrow therapeutic window and some dispute on its effectiveness in 
preventing bone fractures, fluoride-releasing implants might be of interest for patients suffering 
from osteoporosis9. Thus, osteoblasts exposed to the dissolution products of bioactive glasses that 
contain fluoride or early doses of sodium fluoride showed increased alkaline phosphatase activity, 
a bone mineralization marker, suggesting that fluoride can target osteoblast differentiation9. 
Regarding CaO and P2O5, although they are present in FastOs®BG in a larger percentage than in 
equivalent medical devices, as can be calculated from Table 2, FastOs®BG CaO/P2O5 ratio is 6.43, 
i.e., it is smaller than 45S5 Bioglass® (10.34) ratio. Relatively high CaO/P2O5 ratio make the glass 
surface highly reactive in physiological environments, , leading to fast degradation rates not 
matching the new bone ingrowth, loosening of the bonding strength to living tissues6,7. Thus, the 
FastOs®BG CaO/P2O5 may offer advantages in relation to the equivalent medical device. In relation 
to SiO2, some studies show that the critical feature for bioactivity is a SiO2 content < 60% in 
weight10. Thus, the bioactivity of FastOs®BG is assured since its SiO2 content in weight is 38.49 
(Table 2). 
In vitro and in vivo tests were performed on FastOsBG bioactive glass using 45S5 Bioglass® as a 
control. In vitro, in a study performed by in human mesenchymal stem cells (hMSC), there was no 
difference between the effect that 45S5® Bioglass and FastOs®BG have on cell proliferation. In 
vivo, a recent study shown that bone remodelling process for FastOsBG is safe and presents 
faster bone regeneration than 45S5 Bioglass11. Due to its composition, mechanism of action and 
intended use, FastOs®BG is equivalent to 45S5 Bioglass. 
 
Regarding β-TCP and MCPM, they are also already widely used in clinical practice. In biomedicine, 
β-TCP is widely used in calcium orthophosphate bone cements and other types of bone 
substitution bioceramics. Dental applications of β-TCP are also known, for instance, pure β-TCP is 
added to some brands of toothpaste as a gentle polishing agent 12. β-TCP first contributes to the 
core of the calcification in the bone defect and then promotes osteogenesis around β-TCP, after 
which the β-TCP is resorbed and replaced by bone. Resorption only occurs by a fluid contributed 
process, which can be justified by the absence of phagocytic cells. This occurs due to acute 
resorption when the blood flow attaches to the surface of the β-TCP and is then surrounded by 
bony granulation tissue. A slow resorption of bone probably occurs afterwards by cells which have 
a phagocytic capability 13. 
On the other hand MCPM is also used in biomedicine as a component of several self-hardening 
calcium orthophosphate cements and it is commonly added to several tooth pastes 12.  
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Due to its composition, mechanism of action and intented use, BonActive®Putty is equivalent to to 
NovaBone Putty®. Therefore, no issues regarding safety or effectiveness are raised by the changes 
in composition between BonActive®Putty and its commercial equivalent NovaBone®Putty. 
 
6. Summary of the clinical data and appraisal 
 
A bibliographic research was conducted by the clinical Researcher in PubMed in order to identify 
clinical studies performed using bioactive glass putties in different situations. The following 
strategy was used in the research: putty, bioglass putty, NovaBone®, or NovaBonePutty®, or 45S5 
putty, or dental putty. NovaBone®, structurally corresponds to 45S5 Bioglass®.  
 
Pubmed was chosen because is a search engine accessing primarily the MEDLINE database of 
references and abstracts on life sciences and biomedical topics. It includes bibliographic 
information for articles from academic journals covering medicine, nursing, pharmacy, dentistry, 
veterinary medicine, and health care. 
 
On the other hand, NovaBone Putty® was chosen because it is substantially equivalent to 
BonActivePutty®, since both products are injectable putties with of bioactive glasses e«in their 
composition (Table 1) and are intended to be used as bone cavity filling materials .  
 
The clinical studies performed feature the following aspects: 
 
• Medical specialties in which the medical devices were applied and clinical conditions for their 
use; 
• Methodological features of the studies; 
• Evaluated medical devices. 
The selection process of publication, as well as the number of publications included and excluded 
from this report are presented in Figure 1. 
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Figure 1 - Identification of publications relating to clinical investigations on the use of putties as bone graft 
substitutes using the search strategy: putty, bioglass putty, or NovaBone®, or NovaBone Putty®, or 45S5 
Bioglass® putty, or dental putty. NovaBone® it structurally corresponds to 45S5 Bioglass®. 
 
 
The 13 articles selected from PubMed were subsequently subjected to a criteria analysis for 
suitability according to Table D1 (in the annex).  
According to our internal criteria, all the items that were considered “other device” (D3), with 
“major deviation” on device application (A3), to consider “different population” group (P3) or with 
“insufficient information” (R3) were considered unsuitable. 
This analysis is present in Table 3. 
Table 3: Publication suitability evaluation  
Article Appropriate 
device 
Appropriate 
device 
application 
Appropriate 
patient 
group 
Acceptable 
report / 
data 
collation 
Suitability  
Evaluation of the efficacy of a bioactive synthetic graft material in the 
treatment of intrabony periodontal defect14 
D2 A1 P1 R2 YES 
Implants placed simultaneously  with lateral window sinus 
augmentation using a putty alloplastic bone substitute for increased 
primary implant stability: A retrospective study15 
D2 A1 P2 R1 YES 
Socket preservation with alloplast: Discussion and a descriptive case16 D2 A1 P2 R3 NO 
A randomized, blinded, controlled clinical study of particulate anorganic 
bovine bone mineral and calcium phosphosilicate putty bone substitutes 
for socket preservation17 
D2 A1 P1 R1 YES 
Human histologic evaluation of the use of the dental putty for bone 
formation in the maxillary sinus: Case series18 
D2 A1 P1 R1 YES 
 
Clinical and cone beam computed tomography comparison of NovaBone 
Dental Putty and PerioGlas in the treatment of mandibular Class II 
furcations19 
D2 A1 P2 R1 YES 
Comparative Evaluation of Coronally Advanced Flap with and without D2 A2 P1 R1 YES 
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Bioactive Glass Putty in the Management of Gingival Recession Defects: 
A Randomized Controlled Clinical Trial20 
Socket Grafting with Calcium Phosphosilicate Alloplast Putty: A 
Histomorphometric Evaluation21 
D2 A1 P1 R1 YES 
Periotest Values of Implants Placed in Sockets Augmented with Calcium 
Phosphosilicate Putty Graft: A comparative Analysis against Implants 
Placed in Naturally Healed Sockets22 
D2 A1 P1 R1 YES 
Treatment of high-energy tibial shaft fractures with internal fixation and 
early prophylactic  NovaBone grafting23 
D3 A1 P1 R1 NO 
Clinical evaluation of 262 oseeointegrated implants placed in sites 
grafted with calcium phosphosilicate putty: a retrospective sudy24 
D2 A1 P1 R1 YES 
Alveolar Ridge Preservation With the Socket-Plug Technique Utilizing an 
Alloplastic Putty Bone Substitute of a Particulate Xenograft25 
D2 A1 P1 R1 YES 
Histomorphometric Evaluation of a Calcium-Phosphosilicate Putty Bone 
Substitute in Extraction Sockets26 
D1 A1 P1 R1 YES 
 
Thus, according to Table 3, 2 articles from the initial 13 were considered unsuitable for this study. 
Subsequently, the data contribution of each of 11 articles selected from Table 3 was evaluated 
according to Table D2 (in the annex). This analysis is present in Table 4. 
According to our internal criteria, when the design of the study was considered inappropriate (T2), 
the outcome measures reported did not reflect the intended performance of de device (O2), the 
follow-up was considered inappropriate (F2), when it was not provided statistical analysis or the 
same was inadequate (S2) or the magnitude of the treatment effect observed was clinically 
insignificant (C2) it was considered that the data did not contribute to the study. 
 
Table 4: Data contribution analysis 
Article Data 
source 
type 
Outcom
e 
measure
s 
Follow 
up 
Statistic
al 
significa
nce 
Clinical 
significa
nce 
Data 
Contribu
tion 
Evaluation of the efficacy of a bioactive synthetic graft material in the 
treatment of intrabony periodontal defect14 
T1 O1 F1 S1 C1 YES 
Implants placed simultaneously  with lateral window sinus augmentation 
using a putty alloplastic bone substitute for increased primary implant 
stability: A retrospective study15 
T1 O1 F1 S1 C1 YES 
A randomized, blinded, controlled clinical study of particulate anorganic 
bovine bone mineral and calcium phosphosilicate putty bone substitutes for 
socket preservation17 
T1 O1 F1 S1 C1 YES 
Human histologic evaluation of the use of the dental putty for bone 
formation in the maxillary sinus: Case series18 
T1 O1 F1 S3 C1 NO 
Clinical and cone beam computed tomography comparison of NovaBone 
Dental Putty and PerioGlas in the treatment of mandibular Class II 
furcations19 
T1 O1 F1 S1 C1 YES 
Comparative Evaluation of Coronally Advanced Flap with and without 
Bioactive Glass Putty in the Management of Gingival Recession Defects: A 
Randomized Controlled Clinical Trial20 
T1 O1 F1 S1 C1 YES 
Socket Grafting with Calcium Phosphosilicate Alloplast Putty: A 
Histomorphometric Evaluation21 
T1 O2 F1 S3 C1 NO 
Periotest Values of Implants Placed in Sockets Augmented with Calcium 
Phosphosilicate Putty Graft: A comparative Analysis against Implants Placed 
in Naturally Healed Sockets22 
T1 O1 F1 S1 C1 YES 
Clinical evaluation of 262 oseeointegrated implants placed in sites grafted 
with calcium phosphosilicate putty: a retrospective sudy24 
T1 O1 F1 S1 C1 YES 
Alveolar Ridge Preservation With the Socket-Plug Technique Utilizing an 
Alloplastic Putty Bone Substitute of a Particulate Xenograft25 
T1 O1 F1 S1 C1 YES 
Histomorphometric Evaluation of a Calcium-Phosphosilicate Putty Bone 
Substitute in Extraction Sockets26 
T1 O1 F1 S1 C1 YES 
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According to the previous analysis (Table 4) 9 articles were selected to contribute significantly to 
this study. 
7. Data analysis  
The selected studies studies14,15,17,19,20,22,24–26, resulting from previous analysis will be described 
below, according to performance (6.1) and safety (6.2).  Subsequently, a performance and safety 
analysis summary is present in Table 5. According to these reports, NovaBonePutty®is used in the 
following medical specialties: dentistry, cranio-maxillofacial surgery and orthopaedics. 
 
 
7.1 Performance  
 
A brief description of the results obtained in the selected studies14,15,17,19,20,22,24–26, and its clinical 
significance regarding the performance is present at this point. These studies were selected as 
those that most contribute to the clinical evaluation of BonActive®Putty and are analyzed in 
chronological order. 
The first clinical research study that relates  the treatment of intrabony periodontal defects using a 
commercially available bioactive glass putty (NovaBone Dental Putty®), was published in 
201314.  The purpose of this study was to evaluate the efficacy of a bioactive synthetic graft 
material (NovaBone Dental Putty®) in the treatment of intrabony periodontal defects. Mean 
radiographic defect fill, with the putty, of 64.76% (2.49 ± 0.5 mm) was observed in 6 months, 
which was statistically significant. A statistically significant relative attachment level gain of 2.71 ± 
1.13 mm and probing pocket depth reduction of 4.21 ± 1.18 mm was recorded at the end of the 
study. A significant decrease in mobility and gingival index was observed. The clinical results of the 
use of bioactive glass putty shows that this biomaterial is an efficacious treatment option for the 
reconstruction of intrabony periodontal defects 14. 
In 2014, Kotsakis and co-workers published several clinical studies using NovaBone Dental Putty® 
for socket extraction or preservation and sinus augmentation15,17,25,26. 
In the first study, the clinical efficacy of an anorganic bovine bone graft particulate (BOV) and a 
calcium phosphosilicate putty alloplast (PUT) (NovaBone Dental Putty®), for socket preservation, 
was compared17. Postgrafting radiograph revealed adequate bone fill in all sockets of the tested 
groups. Both test groups had statistically significant reduction in mean ridge width (BOV: 1.39 ± 
0.57 mm; PUT: 1.26 ± 0.41 mm) in comparison to the control group (no graft or suturing) (2.53 ± 
0.59 mm). No statistically significant difference was identified between the test groups. The 
maximum implant insertion torque (MIT) for PUT was ≤ 35 N/cm2 (MIT grade 4) for seven of the 
nine implants. MIT values in the BOV group ranged from grade 1 (10 to 19 N/cm2) to grade 4, 
which was statistically significantly lower than for the PUT group. The overall implant success rate 
was 94.1% and no implants were lost in the PUT group (failure of one implant in the BOV group). 
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According to the authors, both bone substitutes can be recommended for alveolar ridge 
preservation following extraction. The calcium phosphosilicate putty might be more suitable for 
achieving primary stability for implants placed at 5 to 6 months postextraction17. 
Later, in another study, was evaluated the bone regeneration in 24 sockets grafted with a calcium 
phosphosilicate putty (NovaBone Dental Putty®). Radiographic analysis during the postextraction 
healing period (5 to 6 months) showed radiopaque tissue in all sockets. Histomorphometric 
analysis revealed a mean vital bone content of 31.76% (± 14.20%) and residual graft content of 
11.47% (± 8.99%) after a mean healing period of 5.7 months. The high percentage of vital bone in 
the healed sites in combination with its timely absorption rate suggest that NovaBone Dental 
Putty®  can be a reliable choice for osseous regeneration in extraction sockets26. 
 
The same authors published another clinical article22, whose aim was to measure the implant 
stability using periotest values of implants placed in sockets augmented with calcium 
phosphosilicate putty (NovaBone Dental Putty®) as compared with implant stability in naturally 
healed sockets. Periotest values were significantly lower in the grafted group, indicating a better 
implant stability in sites grafted with NovaBone Dental Putty®. The results suggests that socket 
grafting with this putty may enhance the quality of available bone for implantation22. 
 
In a retrospective clinical study15, Kotsakis et al. evaluated the primary stability of implants (5 mm 
of bone height were included as controls and NovaBone Dental Putty®) placed in significantly 
pneumatized maxillary sinuses with minimum residual bone height. A total of 30 (15 controls and 
15 NovaBone Dental Putty®) implants were inserted with a maximum insertion torque number ›20 
N/cm2. Logistic regression analysis failed to show any association between residual bone height 
and primary implant stability. The diminished preoperative vertical dimensions of the residual 
ridges did not seem to negatively influence the osseointegration of implants placed in this study15. 
Therefore the plenitude of human clinical studies have verified the osseous regenerative potential 
of this putty15. 
 
Also in 2014, a bioglass particulate, PerioGlas®, was compared to Novabone Dental Putty® in the 
treatment of mandibular Class II furcations19. There was no significance between group 
differences in clinical parameters and defect size at the baseline. After 6 months, PerioGlas® 
showed a mean resolution of 50.48 ± 16.47% and 51.11 ± 9.48%, respectively for vertical defect 
and horizontal defect while the putty form showed a mean resolution of 43.48 ± 9.33% and 42.88 
± 11.09%, respectively. Mean resolution in furcation width was 40.15 ± 13.00% for particulate 
form as compared with 36.27 ± 11.41% in putty form. Statistically, there was no significant 
differences between the two groups except for the horizontal defect fill where PerioGlas® showed 
statistically significant better results. These results demonstrated that the use of both the forms of 
bioactive glass, that is putty and particulate, effectively regenerated Class II furcation defects with 
an uneventful healing of the sites19. 
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More recently, in 2015, Babbush & Kanawati clinically evaluated 262 osseointegrated implants in 
sites grafted with a calcium phosphosilicate putty (Novabone Dental Putty®)24. The aim of this 
study was to report the clinical efficacy of calcium phosphosilicate (CPS) putty in a wide variety of 
indications related to implant reconstruction and to report the survival rate of implants placed in 
these grafted sites. Treatments were categorized into following groups: extraction graft, 
extraction with immediate implant placement, all-on-four concept, peri-implantitis treatment, 
bone augmentation before implant placement, implant replacement graft, and grafting around 
implant placed in resorbed ridges. Four implants for a total of 266 grafted sites were diagnosed 
with peri-implantitis and were treated as with peri-implantitis treatment. The implant success rate 
at 1 year was 98.1%. The use of this putty as a bone graft can simplify bone-grafting procedures 
and reduce intraoperative time in various grafting indications with efficacy and very high survival 
rates24. 
 
Also in 2015, Kotsakis el al., histologically evaluated and compare bone regeneration in extraction 
sockets grafted with either a putty alloplastic bone substitute (Novabone Dental Putty®)  or 
particulate anorganic bovine xenograft utilizing the socket-plug technique25. A bone core was 
obtained during the implant procedure from each site and was used for histologic analysis. 
Histomorphometry revealed that residual graft values were significantly higher in the bovine 
xenograft group (25.60% 6 5.89%) compared to Novabone Dental Putty® (17.40% 6 9.39%) 
(p<0.05). The amount of new bone regenerated was also statistically significant higher in 
Novabone Dental Putty® group (47.15% 6 8.5%) as compared to the xenograft group (22.2% 6 
3.5%) (P<0.05). The results suggest that ridge preservation using Novabone Dental Putty® 
demonstrates more timely graft substitution and increased bone regeneration when compared to 
an anorganic bovine bone xenograft25. 
 
The latest clinical study was published in 201620. The authors clinically evaluated the outcomes of 
Coronally Advanced Flap (CAF) with and without NovaBone® bioactive glass putty, in terms of root 
coverage, gains of keratinized tissue height and root coverage aesthetic score in multiple gingival 
recession (GR) defects20. Six months post-surgery all clinical parameters showed significant 
reductions. Gingival recession showed significant reduction both in test and control groups (2.0 ± 
0.47 mm and 2.3 ± 0.48 mm, respectively; p<0.05) with no intergroup difference. The exposed 
root was covered by 72% (test) and 79% (control). Clinical attachment level (CAL) gain was also 
significant in both groups (test: 2.7 ± 0.67 mm; control: 2.8 ± 0.78 mm; p<0.05) with no intergroup 
difference. Keratinized tissue height (KTH) gain was significant in both the groups (test group: 1.2 ± 
0.42 mm; control group: 0.9 ± 0.57 mm) with no intergroup difference. Also, the root coverage 
esthetic score (RES) was significant for both the test and control groups (7.2 ± 2.78 and 7.7 ± 1.41 
respectively) with no intergroup differences. In isolated Class I/II GR defects, CAF associated with 
bioactive glass putty provided no significant difference in root coverage, CAL, KTH or RES 
compared to CAF alone. However, statistically significant gains were seen in all the parameters in 
both groups as compared to baseline20. 
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7.2 Safety 
 
The safety of each of the selected articles 14,15,17,19,20,22,24–26 is then individually analyzed. 
Grover et al. 14 studied the efficacy of Novabone Dental Putty® in twelve systemically healthy 
subjects (fourteen intrabony defects), 8 men and 4 women, having moderate to severe chronic 
periodontitis. Patients were evaluated after bone grafting with the Novabone Dental Putty® for a 
period of 6 months. Clinical and radiographic evaluations were made at baseline, and 3 and 6 
months following surgery. All the treated sites resulted in uneventful healing. No complications 
such as allergic reaction, abscesses, or infections were observed throughout the study period, in 
any of the patients. Safety characteristics and intended purpose of the device does not require 
specific training in addition to the surgical doctor training. 
 
In their 2014 study, Kotsakis and colleagues17 extracted thirty teeth from 24 patients (17 men, 9 
women). In order to compare the clinical efficacy of an anorganic bovine bone graft particulate to  
Novabone Dental Putty® for socket preservation, The sockets were debrided and received 
anorganic bovine bone mineral (BOV, n=12), calcium phosphosilicate putty (PUT, n=12), or no graft 
(CTRL, n=6). The sockets were assessed clinically and radiographically 5 months later. Eight sockets 
in the BOV group and nine in the PUT group received implants 5 to 6 months postgrafting. The 
maximum implant insertion torque (MIT) was measured as an index of primary implant stability. 
The data were analyzed with the Mann-Whitney test. Intraoral clinical examination revealed 
healthy peri-implant mucosa without clinical signs of inflammation of the peri-implant tissues. All 
osseointegrated implants functioned well during the follow-up period, for a cumulative 
postloading success rate of 100%. The authors did not report the occurrence of any side effects 
arising from the use of Novabone Dental Putty®. Safety characteristics and intended purpose of 
the medical device does not require specific training in addition to surgical training17. 
 
Later on, Kotsakis et al.26 have made a histomorphometric evaluation of Novabone Dental Putty® 
in extraction sockets in twenty-four patients (11 men and 13 women). Patients were scheduled for 
tooth extraction and ridge preservation. Pre and immediate postoperative radiographs were 
obtained. Post-operative evaluations were performed at 7 and 14 days and at 4 weeks to assess 
wound healing and record any adverse events. Following 5 to 6 months of healing, surgical re-
entry was performed on patients that decided to proceed with implant placement at the healed 
sites to clinically evaluate the regenerated bone in the original defect and to retrieve a bone 
biopsy specimen. All 24 treated sites healed without complications. No incidence of alveolar 
osteitis was reported in any of the treated sockets. A limitation of this study is the multicenter 
design. Even though a calibration session was provided to minimize any clinician related variations, 
the relatively high standard deviation values noted in new bone formation may be attributed to 
the multiple operators located in different settings. The authors didn’t report any complications 
related with putty utilization. In addition to surgical training, no special training by the user doctor 
was necessary26. 
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In Shukla et al. 2014 study22, twenty two sockets were implanted with Novabone Dental Putty® 
immediately after extraction. The sockets were re-entered after a healing period at 5 to 6 months 
(average of 5.3 months) for implant placement. Periotest values were recorded during implant 
insertion to assess primary stability. These were compared with the Periotest values of 26 
implants placed in 22 patients, with naturally healed sockets. Safety characteristics and intended 
purpose of the device does not require specific training in addition to the surgical doctor training. 
 
In another study, Kotsakis et al.15 also evaluated the primary stability of implants, using Novabone 
Dental Putty®, in seventeen patients with a median age of 51 years old. All patients contributed 
with at least 1 direct sinus lift procedure. After implant loading, patients were clinically evaluated 
after 6 months and then followed up on an individualized basis, which included clinical 
examinations at least biannually. No patients experienced any complications associated with the 
sinus surgery or implant placement15. Safety characteristics and intended purpose of the device 
does not require specific training in addition to the surgical doctor training. 
 
The Asmita et al. study19 included 28 patients with 40 Class II furcation defects, that were treated 
with Novabone Dental Putty® and PerioGlas® particulate. Measurement of defects was done using 
clinical and cone beam computed tomography (CBCT) methods. The patients were followed-up at 
6 months. Intergroup comparisons were done using Mann- Whitney U-test19 All the patients were 
compliant and healing was uneventful for both groups. Safety characteristics and intended 
purpose of the device does not require specific training in addition to the surgical doctor training. 
 
In their retrospective study, Babbush & Kanawati 24 reported the efficacy of Novabone Dental 
Putty® in several treatments: extraction graft, extraction with immediate implant placement, all-
on-four concept, peri-implantitis treatment, bone augmentation before implant placement, 
implant replacement graft, and grafting around implant placed in resorbed ridges. 65 patients 
were included in this study (36 men, 29 women) with a mean age of 63 ± 12 years. In total, 262 
implants were placed. Four implants were diagnosed with peri-implantitis and were treated as, for 
a total of 266 grafted sites. Two implants from the extraction graft category and 3 implants from 
the all-on- four group were lost and replaced with successfully osseointegrated implants during a 
mean study follow-up period of 12.24 6 2.32 months24. Safety characteristics and intended 
purpose of the device does not require specific training in addition to the surgical doctor training. 
 
In their 2015 pilot study, Mahesh et al. 25 histologically evaluated and compared the quality of 
bone formation in extraction sockets following implantation with either Novabone Dental Putty® 
or Bio-Oss® in nineteen patients. All patients underwent 20 tooth extractions and ridge 
preservation following a standardized protocol. Patients were recalled after 4–6 months to 
evaluate the bone regeneration and to proceed with implant placement. A bone core was 
obtained during the implant procedure from each site and was used for histologic analysis25. 
Safety characteristics and intended purpose of the device does not require specific training in 
addition to the surgical doctor training. 
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Latter, in 2016, Bansal et al.20 included in their ten healthy patients (age range 18-45 years) with 
multiple bilateral (n=40: test 20, control 20) and comparable Miller’s Class I or Class II gingival 
recession defects. The defects were randomly assigned by a computer-generated list to either test 
(Coronally Advanced Flap + Novabone Dental Putty®) or control (Coronally Advanced Flap alone) 
groups. Clinical parameters included gingival recession (GR), probing pocket depth (PPD), clinical 
attachment level (CAL), keratinized tissue height (KTH) and root coverage esthetic score (RES) 
evaluated at baseline and at 6 months post-surgery CAF with or without bioactive glass putty20. 
Safety characteristics and intended purpose of the device does not require specific training in 
addition to the surgical doctor training. 
 
 
7.3 6.2.1 Surveillance safety survey 
 
On October 2016, a survey was carried out on all alerts published during the last 20 years on the 
FDA MAUDE website. A search was performed using NovaBone Putty® as a term. 
 
Four occurrences concerning NovaBone Putty® were reported: 
 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=4766623 27 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=4766615 28 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=4763070 29 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=4763064 30 
In two of the cases referred above 28,30 two patients have experienced a staph infection after 
surgery to implant pioneer surgical devices as well as NovaBone Putty®. Pioneer surgical has 
submitted medical device reporting related to these two cases. Both patients contracted staph 
infections. Site irrigation was performed on each and both patients were placed on antibiotics. 
Both patients were released after 3 days from the hospital. In each of the other two occurrences 
27,29 one patient was admitted with infection after surgery. Surgery was anterior cervical 
discectomy and fusion backup an up later with metal from Biomet. These complications are 
directly related to the surgical procedure and not to NovaBone Putty®. 
For all these events, the manufacture found that manufacturing, sealing and sterility records verify 
product was manufactured according to specifications with no deviations or non-conformances 
associated with the lot.  
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On October 2016, a search on the MHRA and Infarmed websites was performed, using NovaBone 
Putty® as a term. No complications were found related to the use of NovaBone Putty® in MHRA 
and Infarmed databases. 
7.4 6.3 Product Literature and Instructions for Use  
 
In addition to this report are available: 
- BonActive®Putty Datasheet (DS 03_01); 
- BonActive®Putty Instructions for Use (IFU 03_01); 
- BonActive®Putty Product Description (PD 03_01). 
 
8. Equivalence statement 
 
BonActivePutty and NovaBone Putty use biocompatible materials that fill bone voids and 
provide an environment for bone regeneration. BonActivePutty is a bone substitute equivalent to 
those on the market with minor differences in the composition. For all these medical devices the 
mechanism of action is the same, i.e. the host bone remodels through an osteoconductive process 
as new bone grows into the porous matrix of the graft materials. The graft materials are slowly 
resorbed and replaced by the host bone. BonActivePutty and NovaBone Putty have the same 
mode of action, therefore no new issues of safety or performance are presented. 
 
The following table (Table 5) makes a comparison between BonActivePutty and NovaBone 
Putty. 
 
 
 
Table 5: Comparison of BonActive®Putty with the equivalent medical device 
Substantial 
equivalence 
comparison 
New Medical Device 
 
Equivalent Medical 
Device 
 
Intended use 
Bioactive and osteoconductive bone void filler device for the 
regeneration of hard tissues. 
Same as new device 
Indications 
Is indicated to be packed into bone voids or gaps to fill and/or augment 
orthopaedics, oral, dental intraosseous and cranio-maxillofacial defects. 
Same as new device 
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Composition 
This is a putty that consists of a mixture between a solid phase 
(FastOS®BG, β-TCP and MCPM) and a liquid phase (Glycerol). It is 
composed solely of elements that exist naturally in normal bone (Ca, P, 
Na, Si, O). 
Putty that consists of 
a mixture between a 
solid phase 
(45S5Bioglass®) and a 
liquid phase (PEG and 
Glycerol) 
Device action 
Ion diffusion and exchange at particle surfaces form a calcium 
phosphate surface layer, which acts as a scaffold for new bone 
formation throughout the graft site via osteoconduction. Continued ion 
diffusion and exchange results in material resorption. 
Same as new device 
Performance 
Bone infiltration occurs throughout the graft site via osteoconduction, 
resulting in increased graft site mechanical stiffness and strength. 
Same as new device 
Bone 
remodelling 
Bioactive and osteoconductive bone void filler device for the 
regeneration of hard tissues. 
Same as new device 
Biocompatibility Biocompatible Same as new device 
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9. Conclusions 
 
BonActivePutty and NovaBone Putty are putties that have bioactive glass in their composition. 
Changes in the composition are related to the use of a different bioactive glass, absence of PEG 
and higher concentration of glycerol in the liquid phase and β-TCP and MCPM addition in the solid 
phase. These differences are properly explained above, since all different components are already 
widely used in clinical practice. Therefore, no issues regarding safety or performance are raised by 
the changes in composition. 
Based on the specifications presented, it can be concluded that the intended use, material 
composition and scientific technology, degradation properties, bioactive, osteoconductive and 
osteostimulative properties of BonActivePutty is substantially equivalent with the equivalent 
medical device, when used in the indications for use described above and do not raise new 
questions of safety and performance. 
In conclusion, the performance and safety of BonActivePutty as claimed in Product DataSheet 
(DS 03_01) and Instructions for Use (IFU 03_01) has been established and no risks associated with 
the use of the device were detected besides those arising from surgery. 
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11. Annex 
 
Table D1: Sample Appraisal Criteria for Suitability  
 
Suitability Criteria Description Grading System 
Appropriate device Were the data generated from the device in 
question? 
D1      Actual device 
D2      Equivalent device  
D3      Other device 
Appropriate device  
application 
Was the device used for the same intended use 
(e.g., methods of deployment, application, 
etc.)? 
A1      Same use 
A2      Minor deviation 
A3      Major deviation 
Appropriate patient  
group 
Where the data generated from a patient group 
that is representative of the intended 
treatment population e.g., age, sex, etc.) and 
clinical condition (i.e., disease, including state 
and severity)? 
P1      Applicable 
P2      Limited 
P3      Different population 
Acceptable 
report/data collation 
Do the reports or collations of data contain 
sufficient information to be able to undertake a 
rational and objective assessment? 
R1      High quality 
R2      Minor deficiencies 
R3      Insufficient information 
 
 
Table D2: Sample Appraisal Criteria for Data Contribution 
 
Data Contribution Criteria Description Grading System 
Data source type Was the design of the study appropriate? T1      Yes 
T2      No 
Outcome measures Do the outcome measures reported reflect the 
intended performance of the device? 
O1      Yes 
O2      No 
Follow up Is the duration of follow-up long enough to assess 
whether duration of treatment effects and identify 
complications? 
F1       Yes 
F2       No 
Statistical significance Has a statistical analysis of the data been provided and 
is it appropriate? 
S1       Yes 
S2       No 
Clinical significance Was the magnitude of the treatment effect observed 
clinically significant? 
C1      Yes 
C2      No 
 
BonActive®Putty  
I n s t r u c t i o n s  f o r  U s e  
 
Reg4life Regeneration Technology, S.A. | IFU 03_01  |2016/10/21 
 
 www.reg4life.com | gera@reg4life.com | +351 213 172 250 
 
Mod 06_01 
Components of the medical device 
Inside the package there is a syringe containing 
BonActive®Putty. All components inside the package are 
sterile. 
 
Description 
BonActivePutty is a synthetic, bioactive and 
osteoconductive bone graft substitute. It is supplied 
sterile and is ready-to-use. This is a medical device which 
consists of a mixture between a solid phase (FastOSBG, 
β-TCP and MCPM) and a liquid phase (Glycerol).  
This medical device can be clinically applied for the 
regeneration of hard tissues. The device is injectable, fast 
absorbed and replaced by new bone tissue during the 
healing process. BonActivePutty is indicated to be 
injected into bone voids or gaps to fill and/or augment 
orthopaedics, oral, dental intraosseous and cranio-
maxillofacial defects. 
BonActivePutty is sterilized by gamma irradiation and is 
available in different syringe units. 
 
Indications for use 
Dentistry 
• Correction of periodontal and furcation defects. 
• Socket regeneration – ridge preservation. 
• Graft material for bone regeneration to be used during 
oral implant surgery. 
 
Cranio-maxillofacial surgery 
• Bone cavity filling in cranio-maxillofacial area including 
the jaw. 
• Frontal or maxillary sinus obliteration. 
 
Orthopaedics 
• Bone cavity filling. 
• Bone cavity filling in the extremities and pelvis. 
• Bone cavity filling in the treatment of bone tumors. 
 
Contraindications 
BonActivePutty should not be applied: 
 
•In acutely or chronically infected tissues at the surgical 
site, 
•To replace structures that are subjected to strong 
mechanical stress, 
•In patients that need chronic anticoagulant therapy, 
•In patients that are taking immunosuppressant therapy, 
•In patients who are receiving chemotherapy or radiation 
therapy,  
•When patients have had or are undergoing bone 
irritation, 
•In patients with known allergy to bioactive glasses, β-
TCP, MCPM, and/or glycerol, 
•In patients with metabolic disease known to adversely 
affect bone healing and mineralization (diabetes, 
hyperparathyroidism, osteomalsia…), 
•In patients with severe hepatic and renal disfunction, 
•In patients that have any existing condition or disease 
that will interfere with good and bone healing. 
 
Interactions with other agents 
None known. 
 
Warnings and precautions 
•BonActivePutty is intended for use only by medical 
qualified professionals. The professionals must be 
familiar with bone grafting and internal/external fixation 
techniques. 
•No studies have been conducted on pregnant women or 
on breastfeeding-women.  For safety reasons, the 
implantation of BonActivePutty is inadvisable during 
pregnancy and breastfeeding. 
•BonActivePutty is not intended for use with defects 
other than those listed in the indications for use. 
 
 
Administration 
Prepare surgical site following standard procedures. 
Thorough debridement of osseous defect is important.  
Step 1. Open BonActivePutty package and aseptically 
remove the syringe from the tray. 
Step 2. Unscrew the cap and plush the plunger to force 
the putty to the defect site. 
Alternatively, push the plunger to force the putty to a 
sterile cup and subsequently perform the implantation 
with a sterile instrument. 
Step 3. In small increments gently fill the defect 
completely with BonActivePutty. Use spoon end of 
spatula, do not pack or compress material into the site.  
Remove any excess material and close as per standard 
practice. Resorbable or non-resorbable membranes may 
be used while closing. 
 
Complications 
Complications may include normal post-surgical related 
symptoms like edema, redness, tenderness, swelling and 
fluid collection in the operation area. 
Complications specific to oral/dental use are those as 
may be typically observed for similar bone grafting 
procedures and may include: tooth sensitivity, gingival 
recession, flap sloughing, resorption or ankylosis of the 
treated root, abscess formation. 
In case of any adverse effects occur, report to the doctor 
and / or manufacturer. 
 
 
Handling  
•Do not use the product if the sterile package is 
damaged. 
•Do not use after the shelf-life. 
•The product must be promptly used after opening 
the package. 
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•The product is a sterile medical device for single use. Do 
not re-sterilize or use leftover material as it may lead to 
contamination and non-functionality of the product. 
 
Storage 
It is recommended to store the package in a dry place at 
room temperature (< 25 °C), away from humidity and 
sunlight. 
Reporting Incidents 
We instigate the communication of any suspect incident 
related with the use of this product. Please see how to 
contact us on page footer. 
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Information of raw materials 
 
a. Starting materials used 
 
Calcium fluoride (CaF2) 
Calcium carbonate (CaCO3) 
Magnesium carbonate (MgCO3) 
Ammonium dihydrogen phosphate (NH4H2PO4) 
Silicon dioxide (SiO2) 
di-Ammonium hydrogen phosphate (NH4)2HPO4 
Calcium nitrate tetrahydrate pure Ca(NO3)2.4H2O 
Calcium phosphate monobasic monohydrate (H4CaO8P2.H2O) 
Glycerol 
 
b. Delivery method 
The raw materials are delivered by carrier. 
 
c. Packaging 
Starting materials are packed in plastic bottles or in poly drums, depending on the purchased 
amounts.  
 
d. Storage conditions 
Materials are stored under a normal temperature and humidity conditions.  
 
e. Preparation before use  
No special preparation procedures are required before use.  
Information on product 
 
a. Sensitive chemical identified/Biocompatibility 
Product is not yet evaluated by in-vitro and in-vivo tests. 
Biocompatibility tests weren’t yet performed. 
 
b. Storage conditions 
It is recommended that material be stored under normal temperature and humidity 
conditions. 
 
c. Distribution conditions 
The medical device is delivered by carrier. 
 
d. Potential users 
Dentists, orthopaedists and maxillofacial surgeons. 
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e. Potential consumers 
Patients needing bone regeneration. 
 
 
f. Especially vulnerable consumers 
This type of medical devices should not be used in patients who have a systemic metabolic 
disorder known to adversely affect bone healing and mineralization, other than primary 
osteoporosis. 
No studies have been conducted on pregnant women or on breastfeeding-women.  For 
safety reasons, the implantation of FastOs®BG is inadvisable during pregnancy and 
breastfeeding. 
 
g. The intended use 
BonActive®Putty is indicated for use as an osseous defect filler for bone regeneration in 
dentistry, cranio-maxillofacial surgery and orthopaedics. Thus, BonActive®Putty indications 
for use are: 
Dentistry 
• Correction of periodontal and furcation defects. 
• Socket regeneration – ridge preservation. 
• Graft material for bone regeneration to be used during oral implant surgery. 
 
Cranio-maxillofacial surgery 
• Bone cavity filling in cranio-maxillofacial area including the jaw. 
• Frontal or maxillary sinus obliteration. 
 
Orthopaedics 
• Bone cavity filling. 
• Bone cavity filling in the extremities and pelvis 
• Bone cavity filling in the treatment of bone tumours. 
 
h. Foreseeable misuse 
There are no foreseeable misuses outside those resulting from surgical technique. 
 
i. Preparation 
BonActive®Putty is supplied sterile in a syringe and is ready-to-use.  
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j. Labelling [form model example, Mod 05] 
 
 
 
k. Specific requirements 
Specific requirements do not exist other than those requires for a surgical intervention.  
 
l. Product shelf-life 
Product shelf-life is determined by ageing tests. 
m. Sterilization 
Product is sterilized by gamma irradiation. Sterilization process is validated. 
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